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ABSTRACT 
Vaccine-induced protection is generally mediated by long-lived antigen-specific 
B cell responses. Most licensed vaccines target pathogens that display relatively low 
variability, but for highly variable pathogens, such as HIV-1, vaccine development is 
more challenging. This thesis is focused on understanding vaccine-induced B cell 
responses against the HIV-1 envelope glycoproteins (Env), a critical vaccine target. 
Information about the immunogenic properties of candidate Env immunogens remains 
limited and so far the elicitation of broadly neutralizing antibodies (bNAbs) were not 
reported for any vaccine regimen tested in primates. Thus, there is a need to investigate 
vaccine-induced B cell responses against Env in more detail and to identify means to 
improve upon current Env-based vaccine strategies. Here, I investigate B cell responses 
in nonhuman primates immunized with soluble HIV-1 Env trimers to address these 
questions, as well as to gain an enhanced understanding about B cell responses to 
complex protein antigens in general. 
In paper I we established several assays for the evaluation of B cell responses 
in macaques. Following immunization with soluble trimeric Env, we comprehensively 
analyzed the B cell responses in the periphery, bone marrow, and mucosal 
compartments and further evaluated the elicited Abs for neutralization activity and 
protection in a SHIV challenge model. We observed high levels of Env-specific B cell 
responses following immunizations, improved breadth of neutralization compared to 
responses elicited by a monomeric Env vaccine tested in humans and delayed 
acquisition of SHIV infection compared to in control immunized animals. In paper II 
we evaluated longitudinal B cell responses following immunization with soluble 
trimeric Env and influenza HA protein, the latter included for comparative purposes. 
We found that peripheral B cell responses declined rapidly following boost, while 
antigen-specific long-lived plasma cells were stable for >6 months following 
immunization, for both antigens. In paper III we established a system for high-
resolution evaluation of B cell responses in nonhuman primates. We first characterized 
the rhesus immunoglobulin loci to allow analyses of Ab gene usage and somatic 
hypermutation. We next isolated monoclonal antibodies (MAbs) targeting the HIV-1 
primary receptor binding site (CD4bs) on Env and we examined the binding 
specificities of these Abs compared to infection-induced MAbs to unravel limitations of 
current vaccine-induced responses. In paper IV we optimized the RT-PCR method 
used in paper III for isolation of Ab V(D)J sequences from rhesus macaque B cells to 
facilitate future use of the macaque model for B cell studies.  
In conclusion, this thesis establishes several methods for the evaluation of B 
cell responses in nonhuman primates and it demonstrates that the soluble HIV-1 Env 
trimers induce potent, but relatively short-lived peripheral B cell responses. 
Additionally, we describe, for the first time, a set of vaccine-induced CD4bs-directed 
MAbs and we characterize their binding and neutralizing properties and discuss the 
implications of these results for improved Env vaccine design. 
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PREFACE 
This thesis will address how antigen-specific B cell responses develop and are 
maintained following immunization with complex viral glycoproteins, with a focus on 
the HIV-1 envelope glycoproteins (Env). Immunizations were performed with well-
characterized recombinant Env trimers in nonhuman primates from the Macaca 
species, as they are highly relevant biological models due to their similarity to humans. 
To enable readers outside of this field to obtain a thorough understanding of the work 
presented in this thesis the introduction will address key areas necessary to understand 
the problems associated with mounting an effective and long-lasting B cell response 
following Env immunization. The main areas that will be addressed are: 
 
• The development and maintenance of antigen-specific B cell responses. 
• A general introduction to vaccines, how they work, and novel technologies. 
• B cell responses to HIV-1 and how the virus evades host immunity. 
• Animal models to study infectious disease, with a focus on nonhuman 
primates. 
Following the introduction I will briefly present the major methods used in the papers 
presented in this thesis and then discuss the results of the papers. 
LIST OF ABBREVIATIONS 
Ab Antibody 
AID Activation induced cytidine deaminase 
AIDS Acquired immunodeficiency syndrome 
ASC Antibody-secreting cell 
BCR B cell receptor 
bNAbs Broadly neutralizing antibodies 
bp Base pair (referring to the number of  nucleotides) 
CD4bs CD4 receptor binding-site 
CDR Complementary determining region 
Con Constant region (of immunoglobulin) 
CoRbs Co-receptor binding-site 
cryo-EM Cryo-electron tomography 
CTL Cytotoxic T lymphocyte 
D Diversity (region in immunoglobulin) 
ELISA Enzyme-linked immunosorbent assay 
ELISpot Enzyme-linked immunospot 
Env HIV-1 Envelope glycoproteins 
FACS Fluorescence-activated cell sorting 
FR Framework 
Gag Group-specific antigen 
GC Germinal center 
HA Influenza hemagglutinin 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
Ig Immunoglobulin 
IgH Immunoglobulin heavy chain 
Igκ Immunoglobulin kappa chain 
Igλ Immunoglobulin lambda chain 
IgL Immunoglobulin light chain 
J Joining (region in immunoglobulin) 
LLPC Long-lived plasma cell 
MAb Monoclonal antibody 
MBC Memory B cell 
MALT Mucosa-associated lymphoid tissue 
MHC Major histocompatibility complex 
Nef Negative factor 
PBMC Peripheral blood mononuclear cell 
PCR Polymerase chain reaction 
Pol Polymerase gene 
RAG Recombination activating genes 
RT Reverse transcriptase 
SHIV Simian/Human immunodeficiency virus 
SHM Somatic hypermutation 
SIV Simian immunodeficiency virus 
TLR Toll-like receptor 
TRIM5α Tripartite motif protein 5α 
V Variable (region in immunoglobulin) 
Vif Viral infectivity factor 
VLP Virus-like particle 
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1 AIMS 
The specific aims of the individual papers were: 
 
Paper I: To evaluate B cell responses in the periphery and bone marrow following 
immunization with soluble trimeric HIV-1 Env and to assess the 
protective effect against mucosal heterologous SHIV challenge. 
 
Paper II: To determine the persistence of B cell responses to soluble HIV-1 Env 
and influenza virus HA following boost to evaluate if HIV-1 Env displays 
non-conventional antigenic properties compared to the HA control 
protein.  
 
Paper III: To characterize the rhesus macaque immunoglobulin loci and to compare 
it with the human counterpart; and to isolate a panel of monoclonal 
antibodies (MAbs) directed toward the CD4bs from immunized rhesus 
macaques and evaluate their functional properties compared to CD4bs-
directed MAbs isolated from HIV-1 infected persons. 
 
Paper IV: To improve the efficiency of antibody sequence isolation from bulk, or 
single sorted, rhesus macaques B cells by adapting an RT-PCR based 
method described for the human system. 
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2 B CELL RESPONSES  
2.1 A BRIEF INTRODUCTION TO B CELL DEVELOPMENT 
The ability of the humoral immune system to respond to and neutralize almost any 
pathogen lies in the diversity and functional properties of the B cell receptor (BCR). 
The functional BCR is constructed via a complex series of gene segment recombination 
events during B cell development in the bone marrow (reviewed in [1]). The BCR is 
then tested for successful rearrangement and for reactivity to self-antigens, a process 
called central tolerance, so that mainly B cells expressing functional BCRs that are not 
self-reactive are released into the circulation. The B cells leaving the bone marrow are 
immature naïve cells and express surface IgM, but upon reaching secondary lymphoid 
organs, such as lymph nodes, gut-associated lymphoid tissues, or the spleen, they will 
develop into mature naïve B cells expressing both IgM and IgD. During the maturation 
a second step of BCR evaluation will occur, where residual B cells expressing self-
reactive BCRs are deleted [2] in a process referred to as peripheral tolerance (for a 
review on tolerance mechanisms, see [3]). Breakdown of tolerance confers a high risk 
of developing autoimmune disorders (reviewed in [4] and [5]) illustrating the 
importance of these mechanisms. 
 
2.2 ANTIBODY STRUCTURE AND GENETICS 
It is estimated that rearrangement of the antibody (Ab) gene segments can yield as 
much as 1011-1015 unique combinations [6, 7], enabling Abs to interact with any 
potential pathogen. This immense diversity originates from the recombination events of 
variable (V), diversity (D), and joining (J) gene segments localized in the 
immunoglobulin heavy (IgH) chain locus and the lambda (Igλ), or kappa (Igκ) light 
chain loci (reviewed in [7, 8]). The numbers of human and rhesus macaque V(D)J and 
constant region genes as well as chromosome locations of said genes are shown in table 
I. The overall homology between humans and rhesus genomes is estimated to ~93% 
[9]. This also applies to the immunoglobulin genes, which are similar both in sequence 
and organization in the chromosomes [10]. Current knowledge suggests that there are 
more V-segment open reading frames (ORFs) in the rhesus macaque genome compared 
to in humans, although a contribution of all V-segments to the functional Ab pool has 
yet to be confirmed. 
 
Table I. Ig gene numbers in humans and rhesus 
 IgH  Igκ  Igλ 
 Chc V D J Cond  Ch V J Con  Ch V J Con 
Humansa 14 47 23 6 9  2 46 5 1  22 39 7 7 
Rhesusb 7 63 30 6 8  13 62 5 1  10 50 6 6 
aRefers to number of functional sequences as determined by IMGT 
bRefers to number of open reading frames as determined by [10-14]. 
cCh, chromosome. dConstant domain 
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Flanking the V, D, and J gene segments are recombination signal sequences (RSS). 
They are composed of highly conserved heptamers and nonamers separated by 12 or 23 
base pair (bp) spacers, corresponding to one or two turns of the DNA helix. The 
recombination of a one-turn spacer with a two-turn spacer is highly favored. In the 
heavy chain locus the V region is flanked by a two-turn spacer, the D region with one-
turn spacers, and the J region with a two-turn spacer. This allows efficient 
recombination between first the D and J segments and then between the V and DJ 
segment (Figure 1). Due to the one-turn spacers on both sides of the D segment it can 
rearrange with the J segment from both the 5’ and 3’ direction via inversion and 
deletion respectively allowing translation in all six reading frames [15]. Following 
transcription of the V(D)J segments they pair with the downstream constant (Con) 
region, which for naïve B cells is the µ-domain, leading to the production of IgM 
BCRs. 
 
The recombination events are critically dependent on recombination activating genes 
(RAG) 1 and 2, which bind the RSS of the donor and acceptor gene segment and 
catalyze double strand DNA breaks, which then form closed hairpin ends [16, 17]. The 
hairpins are digested via exonuclease activity and joined by non-homologous end-
joining (NHEJ) (reviewed in [18]). In the process of NHEJ palindromic sequences can 
be added (called P-nucleotides) [19], additionally the enzyme terminal 
deoxynucleotidyl transferase (TdT) will be recruited and catalyze the incorporation of 
random non-germline encoded nucleotides (called N-nucleotides) in the heavy chain V-
D, D-J, and light chain V-J junctions contributing greatly to the diversity of the  
complementary determining region 3 (CDR3; see further description of the CDRs 
below))  [20]. The combined effects of imprecise hairpin digestion and the insertion of 
P- and N-nucleotides gives rise to the junctional diversity accounting for a large portion 
of the total variation estimated in the Ab repertoire. 
 
Figure 1. Heavy chain VDJ gene 
rearrangement. First the diversity 
(D) and joining (J) segments 
recombine. This is followed by 
recombination of a variable (V) 
and the DJ segments, forming a 
VDJ gene. After transcription the 
RNA is spliced to remove an 
intron between leader 1 (L1) and 
leader 2 (L2) and between the J 
segment and the first downstream 
constant region. The spliced L1 and L2 correspond a signal peptide that directs the antibody mRNA to 
the rough endoplasmic reticulum and is removed in the translation process. In un-switched cells the 
constant region is the µ-chain giving rise to IgM antibodies. 
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Following the formation of a rearranged IgH VDJ and Ig light (IgL) VJ chain they will 
be produced as heterodimeric proteins that can either be expressed in the form of 
membrane-bound BCRs or secreted in the form of soluble antibodies. The antibody is 
divided into a constant and variable domain, where the IgH VDJ and IgL VJ make up 
the variable domain, while the constant domain is made up from germline encoded 
constant regions (Figure 2A). It is the constant regions that mediate Fc functions, via 
binding to complement and Fc receptors (reviewed in [21, 22]), while the variable 
regions bind the antigen. In humans there are nine IgH constant regions: µ, δ, γ3, γ1, 
α1, γ2, γ4, ε, and α2 (in order of appearance in the genome), and in rhesus macaques 
there are eight, as only encode a single α region is encoded [14]. Instead, the rhesus α 
region displays considerable allelic heterogeneity [12]. The different constant domains 
are associated with optimal effect against different types of pathogens, and anatomical 
locations. IgG1 and IgG3 are associated with responses to viruses, IgG2 with 
encapsulated bacteria, IgG4 and IgE with large extracellular parasites and allergic 
responses, and IgA with mucosal pathogens. The variable VDJ and VJ domains are 
further divided into framework (FR) regions 1-4 and CDR1-3. (Figure 2B) [15, 23]. 
During Ab maturation (covered in section 2.3.1) nucleotide alterations are mainly 
introduced in the CDR while the FR is kept conserved, possibly due to constraints in 
the variable domain folding, which is dependent on β-sheets formed by the FR. 
Additionally, FR2 and 4 form hydrophobic cores that interacts between the heavy and 
light chains. This folding exposes the highly variable heavy and light chain CDR3 
region on the apex of the Ab molecule, increasing the likelihood of antigen interaction 
[24, 25]. 
 
 
Figure 2. Schematic representation of an antibody. (A) Structural regions of an antibody including heavy 
and light chain variable and constant regions. The variable region is composed of rearranged V(D)J-
segments and the constant regions of germline encoded constant domains. (B) Schematic of heavy (IgH) 
and light (IgL) chain frameworks (FR) 1-4 and complementary determining regions (CDR) 1-3 within the 
rearranged VDJ and VJ segments. The same color scheme is used throughout the figure with V (dark 
gray), D (light gray), J (white), and the constant region (black). 
 
2.3 ANTIBODY DIVERSIFICATION 
Following V(D)J recombination the Ab genes can further diversify via two 
mechanisms; Somatic hypermutation (SHM) and class-switch recombination (CSR). 
Both mechanisms are critically dependent on the action of the protein activation-
induced (cytidine) deaminase (AID), which is upregulated in B cells participating in the 
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germinal center (GC) reaction following antigen-BCR interaction [26-28]. AID 
mediates deamination of cytosine (C) to uracil (U), which is mutagenic when paired 
with guanosine (G) in DNA. Uracil mimics thymidine (T) and during replication the 
U:G mismatch triggers error-prone DNA repair, which leads to mutations at the site of 
deamination (reviewed in [29, 30]). Deaminations are mainly introduced in WRC and 
WGCW (W=A or T, R=A or G) hotspot motifs [31, 32] and are dependent on ongoing 
transcription [33, 34].  
 
2.3.1 Somatic hypermutation 
Mutations in the V(D)J genes start to appear ~100 bp after the transcription initiation 
site (promoter) and drops off after ~1 kbp, limiting the variability to the Ig genes [35]. 
Following AID induced C to U deamination, there are at least three mechanisms for 
repair that can introduce mutations (Figure 3) [30, 36]. (1) During cell division and 
DNA replication, the U is read as a T introducing an adenine (A) in the corresponding 
strand. (2) The U is excised via uracil DNA glycosylase (UNG) resulting in a 
noninstructive abasic site. Upon replication or DNA repair, any of the nucleotides A, T, 
G, or C can be incorporated. (3) The U:G mismatch triggers the recruitment of the 
mismatch repair heterodimers MSH2 and MSH6.  MSH2 associates with exonuclease 1 
that creates single-stranded sequence gaps. These gaps are then repaired by error-prone 
DNA polymerases. This mechanisms seems important for mutations in germline 
encoded A:T nucleotides [37]. 
 
 
Figure 3. Mechanisms for AID-induced mutations in the V(D)J region. AID catalyzes the deamination of 
cytosine (C) to uracil (U), which is mutagenic in combination with guanine (G). The deamination can be 
repaired in at least three ways that leads to changes in the base pair sequence. (1) Upon replication the U 
can be recognized as a thymidine (T) leading to the formation of a T:A pair at the site of deamination. (2) 
Uracil DNA glycosylase (UNG) can excise the U leading to an abasic site. This can be repaired by error-
prone polymerases or act as a noninstructive base in DNA replication leading to the insertion of any of 
the nucleotides (A, T, C, or G). (3) The mismatch repair dimers MSH2 and 6 oversee the generation of 
single-strand gaps spanning several nearby nucleotides. The gaps are then repaired by error-prone DNA 
polymerases. N indicates either of the nucleotides A, T, C, or G. W indicates nucleotides A or T. 
 
  6 
2.3.2 Class-switch recombination 
CSR results in the exchange of one Ab constant domain for another while retaining the 
rearranged Ab variable domain allowing for the B cells to respond to different types of 
pathogens. In activated mature naïve B cells, the exchange is by default IgM and IgD to 
a downstream constant domain, determined by the type of innate stimuli and the 
cytokine milieu associated with the antigenic challenge [38-40]. CSR starts with the 
recruitment of AID to 5’-AGCT-3’ repeats, which are highly concentrated in the switch 
regions preceding the constant domains and are accessible due to ongoing transcription. 
AID catalyses the deamination of cytosine on both strands and the resulting UNG and 
MSH2 base excision leads to DNA double strand breaks [41]. This leads to 
juxtapositioning of the two switch regions and following repair and ligation, the 
deletion of the region in between in the form of an extrachromosomal circle (Figure 4) 
[30, 37]. 
 
Figure 4. Class-switch recombination 
(CSR) from the constant µ/δ to γ1 
region. AID deaminates cytosine on 
both DNA strands. UNG and MSH2 
mediate base excision forming double 
strand breaks. The switch regions are 
juxtaposed and following DNA break 
repair form an extrachromosomal 
circle. Since the γ1 constant domain is 
now most proximal to the VDJ region, 
IgG1 antibodies will be produced. The 
cell still retains the capacity to change 
to an isotype further downstream. 
 
 
2.4 B CELL RESPONSES TO ANTIGEN STIMULATION 
When a mature naïve B cell encounters its cognate antigen it will be internalized, 
processed and presented on MHC class II molecules. The required affinity to active the 
naïve BCR is ~1 µM [42], however, this threshold can be reduced to 50 mM if the 
antigen can support BCR cross-linking to increase the avidity effects [43]. Following 
BCR ligation, the B cell will be activated leading to upregulation of CCR7 and EBI2, 
which are important for B cell homing to the interface between the T cell and B cell 
zones of secondary lymphoid organs, where B cell can receive T cell help [44, 45]. 
After 1-2 days at the B/T interface, surviving B cells will either enter the germinal 
center (GC) reaction or become extrafollicular plasma cells [46]. The decision to 
become an extrafollicular plasma cell or GC B cell is in part dependent on BCR 
affinity, with lower affinity B cells entering the GC program [47]. B cells with higher 
affinity BCRs were shown to display increased presentation of MHC class II-restricted 
peptides making them more competitive for CD4+ T cell help at the initial B/T 
interface, which stimulates rapid plasma cell differentiation [48]. In the GC reaction, 
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CD4+ T cell help is mediated by follicular T helper cells characterized as CXCR5+ 
CCR7- CD4+ cells that express Bcl-6 and produce IL-21 [49]. 
 
B cells designated for the GC reaction also upregulate Bcl-6, a transcription factor that 
promotes their survival and repress premature differentiation into memory and plasma 
cells [50, 51]. Furthermore, expression of CXCR5 allows the cells to move toward 
follicular dendritic cells (FDC) in the light zone where they sample cognate antigen and 
receive T cell help [52], after which they move to the dark zone where they proliferate 
extensively and undergo SHM [53, 54]. Evaluation of improved or reduced BCR 
affinity takes place in the light zone by sampling antigens presented by FDCs, where 
higher affinity clones outcompete lower affinity clones [55]. However, there appears to 
be an affinity roof at ~0.1 nM as affinities higher than this do not lead to a higher 
peptide-MHC II load, and therefore no further competitive advantage [42, 56]. At these 
affinities there is therefore no further need for Ab SHM.  
 
2.5 B CELL MEMORY 
B cell memory alludes to B cell derived responses that persist long after clearance of 
the antigen that initially generated the response. It is mainly composed of two cell 
types; Memory B cells (MBC), which are quiescent circulating cells expressing surface 
bound BCR, but do not produce Abs (reviewed in [57]) and long-lived plasma cells 
(LLPC), which mainly reside in the bone marrow and continuously produce large 
amounts of Abs without the need for re-stimulation by antigen (reviewed in [58, 59]). 
The majority of both cell-types originates from the GC, have undergone SHM, display 
high affinity and are often class-switched, all of which are desired properties of 
successful vaccines. These are the cells the current PhD thesis focuses on. 
 
MBCs were shown to persist at low levels without the presence of cognate antigen or T 
cell help for long periods of time [60-62]. They are mainly localized in proximity to 
secondary lymphoid organs and especially the spleen to increase the chance of antigen 
encounter [63-65]. MBCs express a reduced activation threshold coupled with an 
increased expression of co-stimulatory molecules and activation markers compared to 
naïve B cells and they can therefore quickly react to antigen challenge [66-69]. Upon 
re-encounter with the cognate antigen MBCs respond by proliferating and 
differentiating into short-lived antibody-secreting cells (ASC) that produce large 
amounts of Abs [70, 71]. Peak IgG responses observed in the periphery following 
immunization or infections are typically reached after 14 days for a primary encounter 
and 7 days following boost, and thereafter wane quickly [72-75] and [paper II].  
 
Although circulating Ab titers derived from LLPCs can be detectable for >100 years 
following immunization [76], LLPCs are not intrinsically long-lived as proposed for 
the MBCs, although they have been suggested to be imprinted with a maximum 
lifespan determined by the magnitude of B cell signaling received at the initiation of the 
immune response [77]. The survival of LLPCs is dependent on the localization to a 
survival niche [59, 78]. The homing to such a niche is mediated through the surface 
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expression of chemokine receptors, where CXCR4 will allow homing to the bone 
marrow (CXCL12 production) [79, 80], CCR5 and CCR28 to the mucosa [81], and 
CXCR3 to sites of inflammation [81]. In the bone marrow the plasma cells will reside 
in close proximity to stromal cells that produce high levels of CXCL12, the ligand for 
CXCR4, and provide interaction between ICAM-1 on the stromal cell and LFA-1 on 
the LLPC [82]. Further, key cytokines implicated in LLPC survival are IL6, APRIL, 
and BAFF [83-85]. Stromal cells are not necessarily the main producer of these 
cytokines, as neutrophils [86], eosinophils [87], basophils [88], and megakaryocytes 
[89] have been implicated as important contributors. 
 
It is not entirely clear where the LLPCs originate from. It is known that the mutation 
level and affinities of Abs encoded by LLPCs is slightly higher than those encoded by 
MBCs [90, 91] allowing Shlomchik and Weisel to hypothesized that there is a temporal 
switch in the GC reaction where MBCs will be produced first, followed by LLPCs [92]. 
Following boost Radbruch et al. proposed that PCs generated by differentiating MBCs 
compete with previously resident LLPCs and displace them for access to the survival 
niche [59]. This hypothesis is supported by observations of both antigen-specific and 
non-specific plasma cells in the circulation after immunization [93]. However, it is not 
clear how such competition would occur. Another recently described mechanism for 
clearing space in the LLPC niche is through selected apoptosis of antigen-specific 
LLPCs via binding of immune complexes to FcRγIIB expressed on LLPCs [94]. As 
immune complexes would be highly prevalent in the circulation following boost this 
would selectively open niche space at a time where new Ab reactivities with potentially 
higher affinity are generated [95]. 
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3 VACCINES TODAY AND TOMORROW 
3.1 A BRIEF HISTORY ON VACCINE DEVELOPMENT 
The concept of vaccination started with Edward Jenner and his discovery in 1796, that 
people previously infected with cowpox were resistant to, or only received mild 
symptoms from infection with the highly pathogenic smallpox virus. He further learnt, 
that if he took material from scabs of a cowpox-infected person and gave to a 
previously unexposed individual, that person would later be protected from smallpox 
infection. The next big discovery to advance the field of vaccinology was the concept 
of attenuation, discovered by Louis Pasteur, where less virulent variants of the 
infectious agent are used for inoculation, inducing protection against challenge but not 
causing disease. 
 
In the beginning of modern vaccinology, vaccines were mainly developed through 
chemical inactivation of whole bacteria or viruses, such as for anthrax and rabies. This 
was followed by attenuation via passaging of viruses in vivo (e.g. yellow fever virus 
and Japanese encephalitis virus) or of bacteria in vitro (e.g. Bacille Calmette Guérin). 
The discovery of cell-culture methods to grow viruses in the mid 20th century, enabled 
attenuation and production of a wider range of live vaccines (e.g. measles, mumps, 
varicella, rubella, and the oral polio virus vaccines). Following the discovery and 
production of whole-particle-based vaccines was the development of subcomponent 
vaccines, where only parts of the infectious agent are used in the vaccine preparation. 
These vaccines were considered safer due to the lack of a replicating pathogen and 
could effectively be given to immune-compromised people. Successful subcomponent 
vaccines include the diphtheria and tetanus toxoid vaccines as well as the vaccines 
against flu, anthrax, and rabies, which are based on crude preparation extracts. Even 
more defined are the recombinant protein vaccines developed for hepatitis B (HBV) 
[96] and human papilloma virus (HPV) [97], where only the actual immunizing antigen 
is produced using recombinant DNA technology and expression in defined production 
cell lines. However, increasing antigen purity often leads to decreased immunogenicity. 
As a consequence, co-administration of immune-stimulatory components, referred to as 
adjuvants, which activates innate immune responses and promote adaptive immunity 
are needed. 
 
3.2 ADJUVANTS 
As several new vaccine candidates currently undergoing clinical trials are based on 
recombinant proteins [98-100], there is an urgent need for improved understanding and 
licensing of improved adjuvants. To date only three adjuvants are approved for clinical 
use in humans, although several others currently undergo clinical trials (reviewed in 
[101] and [102]). Currently approved adjuvants include Alum, which is based on 
aluminum salts and has been in clinical use for almost a century. Alum was recently 
found to stimulate the immune response via activation of the inflammasome [103, 104], 
although redundant mechanisms have been suggested [105]. Other adjuvants approved 
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for clinical use are MF59, a water-in-oil emulsion [106], and AS04, a combination of 
Alum and monophosphoryl lipid A. Monophosphoryl lipid A is a ligand for toll-like 
receptor 4, suggested to enhance local cytokine production, improving the activation of 
antigen-presenting cells (APCs)  [107]. 
 
Iscoms, Iscomatrix™, and Matrix™ are experimental adjuvants that have been 
evaluated in both preclinical and clinical trials [108-110]. They are cage-like structures 
that are formed when mixing purified fractions of Quillaia saponaria extracts, 
cholesterol, and phospholipids. For Iscomatrix™ and Matrix™ the adjuvant is mixed 
with the antigen in solution at the time of inoculation, while for Iscoms the antigen is 
incorporated into the cage-like structures under denaturing conditions during the 
preparation, limiting their use as conformational B cell epitopes may be disrupted by 
the treatment. These adjuvants induce strong innate cytokine responses and efficient 
priming of B cells and CD4+ T cell responses and even some CD8+ T cell responses 
through cross-presentation [109, 111, 112]. The humoral immune responses typically 
show a balanced Th1/Th2 profile (reviewed in [113] and [110]). For papers I and II 
presented in this thesis, the Abisco-100 adjuvant based on the Matrix™ technology was 
used in combination with the toll-like receptor (TLR) 9 ligand CpG-ODN. The addition 
of TLR-ligands to non-TLR based adjuvants was shown to improve immune responses 
in some settings [114-116]. 
 
In addition to being required for the induction of de novo immune responses to purified 
protein antigens, adjuvants may be used to improve responses of vaccines that work 
poorly in the elderly or in partly immune compromised individuals [117]. The addition 
of an adjuvant also enables a reduction of the antigen dose necessary for the 
immunization, an important aspect if large numbers of vaccine doses have to be 
produced quickly, such as during epidemics or pandemics [118, 119]. For influenza 
vaccination, the addition of the MF59-adjuvant has also been suggested to increase the 
breadth and affinity of the antigen-specific Ab repertoire [120, 121], but whether the 
inclusion of adjuvants allow additional specificities to be recruited into the immune 
reaction remains to be shown. 
 
3.3 CORRELATES OF VACCINE PROTECTION 
To enable the evaluation of vaccine candidates in clinical and preclinical research 
accurately it is important to determine correlates of vaccine protection. For many of the 
currently licensed vaccines, correlates or surrogate markers have been established, 
although most are based on empirical evidence rather than known mechanisms of 
protection (reviewed in [122, 123]) (Table II). For almost all vaccines, Abs have been 
shown to correlate with protection from infection [122]. However, as discussed by 
Plotkin (2010), there are several confounding factors to consider when examining 
potential correlates. For example, high pathogen challenge dose might overcome 
vaccine-induced immunity. Furthermore, the mechanisms of protection from infection 
is not necessarily the same as recovery from infection, illustrated by the need for Abs to 
protect against infection to occur, but cell-mediated immunity to resolve an ongoing 
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infection [124, 125]. For antibody responses, both specificities and effector functions 
are important [126-129], and the capacity of different vaccines to stimulate these 
features may vary between different age groups [130, 131]. Also, the immune system 
has developed redundancy, where several different mechanisms can mediate protection 
against, or resolve, an infection individually if necessary. As shown for the HBV 
vaccine, protection is not necessarily lost because antibody titers fall below the 
threshold of detection; vaccine-induced memory can induce swift and potent responses 
abrogating infection [132, 133]. Furthermore, correlates of protection may vary due to 
the genetic characteristics of different individuals, in particular their major 
histocompatibility complex (MHC) expression [134, 135]. 
 
Table II. Correlates and surrogates for vaccine protection and estimated longevity. 
Licenced vaccines 
(USA) 
Read-out 
[122] 
Antibody half-life  
Years (CI) [76] 
Anthrax Toxin neutralization  
Diphtheria Toxin neutralization 19 (14-33) 
Hepatitis A ELISA  
Hepatitis B ELISA  
Hib polysaccharides ELISA  
Hib conjugate ELISA  
Human papillomavirus ELISA  
Influenza Hemagglutinin inhibition  
Japanese encephalitis Neutralization  
Lyme disease ELISA  
Measles Microneutralization 3014 (104-∞) 
Meningococcal Bactericidal  
Mumps Not certain 542 (90-∞) 
Pertussis ELISA (toxin)  
Pneumococcus ELISA; opsonophagocytosis  
Polio Neutralization  
Rabies Neutralization  
Rotavirus Serum IgA  
Rubella Immunoprecipitation 114 (48-∞) 
Tetanus Toxin neutralization 11 (10-14) 
Smallpox Neutralization 92 (46-∞) 
Tick-borne encephalitis ELISA  
Tuberculosis Interferon  
Varicella FAMA* gp ELISA 50 (30-153) 
Yellow fever Neutralization  
Zoster CD4+ cell; lymphoproliferation  
      *FAMA, Fluorescent antibody to membrane antigen 
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3.3.1 Specificity of the response 
A critical factor for effective vaccine-induced responses is the production of highly 
specific antibodies. For many of the current vaccines it is still unclear what sub-
specificities mediate protection and in some cases total antigen-specific ELISA titers 
from serum is enough as correlate (Table II). However, for infectious agents that 
readily escape immune recognition it is important to promote the production of 
antibodies targeting conserved epitopes, which are not subject to variation. It would 
therefore be helpful to gain an improved understanding about the specificities 
successful vaccines elicit and to build on this knowledge when designing vaccines 
against challenging new vaccine targets. 
 
Much of the knowledge regarding Ab specificities to current vaccines comes from the 
analysis of plasma or serum responses. Smallpox vaccination has been studied 
extensively due to the life long immunity provided (reviewed in [136]). Smallpox 
antigen-arrays have indicated Ab reactivities toward a large portion of the surface 
proteins [137] and Ab binding to several of these surface proteins was shown to 
neutralize the virus independently of each other, indicating functional redundancy 
[138]. These studies are important as they improve our understanding of protective 
immune responses to viral vaccines. 
 
Recent studies have characterized the antigen-specific Ab repertoire, at the clonal level, 
following tetanus toxoid vaccination [139, 140]. These studies provide valuable 
information regarding repertoire breadth, affinity maturation, and clonality following 
sequential protein immunization in a depth not previously performed. The monoclonal 
Abs (MAbs) were isolated and cloned from plasma cells six days after boost [141]. 
Similar approaches were performed following immunization with influenza antigens 
[73] and smallpox [142] and following HIV-1 infection [143]. For the 150 kDa tetanus 
toxoid antigen it was estimated that a standard vaccination scheme stimulated a 
repertoire composed of ~100 clonally different Ab lineages [140]. Further boosting did 
not expand the amount of distinct clones, nor increase SHM rates, indicating that 
maximal levels were reached. There was, however, a slower average off-rate, 
translating to slightly higher affinity [139]. The level of affinity reached was between 
10 µM and 10 pM with an average of  ~1 nM, approaching the suggested upper limit 
[42, 56]. This affinity was reached with IgH SHM rates of 10-15% at the amino acid 
level. Similar SHM levels and affinities were observed for influenza vaccination [73, 
144] and following HIV-1 Env immunization of rhesus macaques [10]. These studies 
show that immunization can induce high levels of SHM, translating into affinities close 
to the suggested maximum roof. However, for HIV-1 many of the broadly neutralizing 
Abs isolated from infected individuals have mutation rates significantly higher than 
20% (amino acid level) [145], indicating that special circumstances might be needed to 
drive the elicitation of such Abs. 
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3.3.2 Durability of the response 
In addition to the elicitation of appropriate specificities, a successful vaccine needs to 
induce a durable immune response. One measurement of durability is the antibody half-
life, which can be measured in circulation, starting six months to 3 years after 
vaccination or infection when peak responses have subsided [60, 75, 76] and [paper II].  
 
The Ab half-life of several vaccines and infections were determined [76, 146] and 
found to vary between 11 years for tetanus to >3000 years for Measles virus (Table II). 
While antibody titers do not always correlate with vaccine protection, as discussed for 
the HBV vaccine above, it is interesting to note that different types of antigens vary 
greatly in the longevity of the response they elicit. Attenuated pathogens, such as 
measles and rubella, induce antibody half-lives of >100 years, while non-replicating 
subunit vaccines, such as the tetanus and diphtheria vaccines induce Ab responses that 
display half-lives of 11 and 19 years respectively [76]. It has been suggested that 
repetitive structures of antigens (e.g. antigen bound to a virus surface) enabling 
extensive BCR cross-linking together with T cell help is important for induction of 
long-lived responses [77]. An additional important factor could be the persistence of 
antigen which is likely different between a replicating vector and a subunit vaccine. 
Unfortunately, it is challenging to perform studies to evaluate the longevity of vaccine-
induced immune responses due to the time and cost required, especially as responses in 
small animal models may not be indicative of responses in humans. 
 
3.4 NEXT GENERATION VACCINE DESIGN 
Despite the success of current vaccines in limiting- and in some cases eradicating 
disease, there are still many infectious agents responsible for high morbidity and 
mortality around the world. For many of these agents the development of new vaccines 
is of high priority (reviewed in [147]). So far, the most potent and effective vaccines are 
based on live attenuated strains that replicate with reduced efficiency in the host. These 
vaccines, however, carry the risk of reverting to pathogenic forms or produce disease in 
immune-compromised people [148, 149]. Therefore, alternative approaches are 
explored to reduce or abrogate virulence factors associated with replicating pathogens. 
For example, target antigens from one pathogen may be express by a non-pathogenic 
vector, such as the expression of respiratory syncytial virus fusion protein in a 
parainfluenza virus, instead of the native surface hemagglutinin [150]. Another 
approach to attenuate live vaccines is the deletion of key virulence factors, as 
performed for dengue virus and polio [151, 152]. 
 
For pathogens, such as HIV-1 and HCV that have a high degree of genetic and 
structural plasticity, live viral vectors containing substantial parts of the genome will 
most likely always be considered hazardous due to the risk of reverting to pathogenic 
forms [153, 154]. Therefore the design of vaccines against these agents is mainly 
focused on the expression of selected antigens, either via recombinant production, 
vector expression systems, or plasmid DNA with the aim of inducing immunity 
targeting conserved regions [155-159]. Furthermore, the approach of using 
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combinations of vaccine modalities, termed prime-boost, has shown to improve vaccine 
efficacy in a HIV-1 phase III clinical study [160] and an experimental smallpox vaccine 
[161], indicating potential positive effects of mixing e.g. viral vectors or DNA to 
induce strong T cell responses followed by boosting with protein to achieve high Ab 
titers. 
 
One method of finding potential antigens is via reverse vaccinology, where the 
genomics of the pathogen is used to screen for potential target antigens, followed by 
expression and functional assays [162]. This approach has been successful in 
identifying targets for group B meningococcus [163] and several other bacterial species 
[164, 165], but not yet for viral pathogens. However, viruses display very few proteins 
on the surface, limiting the need of reverse vaccinology approaches. For viruses where 
the surface proteins contain substantial diversity, an understanding of conserved 
naturalization-sensitive regions will be more important [166]. For several highly 
variable viruses, Influenza [167, 168], HCV [169], and HIV-1 [145], potently 
neutralizing MAbs have been isolated. By crystallizing Ab-antigen complexes as well 
as native antigens an improved understanding of how neutralization is achieved can be 
reached [155]. The knowledge can then be applied in structure-based vaccine design, 
where recombinant vaccine-candidates can be generated and tested through rational 
design [170, 171]. A more focused approach is to graft the epitope of interest onto 
scaffold proteins, unrelated to the pathogen [172]. By consecutively immunizing with 
different scaffolds expressing the same epitope of interest the immune response should 
focus on the grafted epitope [173, 174]. 
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4 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) 
4.1 INTRODUCTION 
Since its discovery, HIV-1 has received substantial attention and a large portion of the 
literature published on infectious diseases every year is directed toward understanding 
HIV-1 pathogenesis and improving HIV-1 vaccine design. These studies suggest that it 
is exceptionally difficult to create a vaccine that protects against HIV-1. It is therefore 
becoming increasingly clear that a thorough understanding of the immunogenicity of 
individual antigens, in particular the surface-exposed Env antigens, and knowledge 
about how HIV-1 evades immune recognition is necessary. These issues are discussed 
below.  
 
4.2 HIV-1 STRUCTURE AND REPLICATION 
HIV-1 is a positive stranded RNA virus, possessing a genome of approximately 9.2 kbp 
and belongs to the Lentivirus genus of the Retroviridae family. Viruses in the 
Retroviridae are enveloped by a lipid membrane, which is derived from the infected 
host cell upon budding. All viruses in the Retroviridae family encode three common 
genes; gag, pol, and env (Figure 5). The HIV-1 gag gene encodes a polyprotein, which 
upon proteolytic cleavage yield the: matrix, capsid, nucleocapsid and p6 proteins. The 
pol gene encodes three enzymes necessary for the viral life cycle; protease, reverse 
transcriptase and integrase, while env encodes the envelope glycoproteins gp41 and 
gp120. HIV-1 also encodes three accessory proteins; Vif, Vpr, Vpu, and three 
regulatory proteins; Tat, Rev, and Nef (reviewed in [175, 176]). 
 
Figure 5. The structure of HIV-1. 
Shown are the gene products of env, 
gag, and pol in the context of the mature 
virion. 
 
 
 
 
 
 
 
HIV-1 binding to the host cell occurs in a two-step process [177]. It is initiated through 
binding of gp120 to the primary host cell receptor, CD4 [178]. This induces 
conformational changes in Env, forming the highly conserved co-receptor binding site 
(CoRbs) [179-182]. The CoRbs then interacts with CCR5 or CXCR4 depending on the 
tropism of the virus [183]. This interaction initiates extensive conformational changes 
in gp41, leading to the formation of the six-helix bundle and subsequent membrane 
fusion [184-187]. Upon entering the cytoplasm the capsid uncoats and the viral RNA is 
released. The RNA is reverse transcribed into double stranded DNA by the error prone 
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reverse transcriptase. The cDNA interacts with the HIV-1 integrase and additional viral 
and cellular components to form the pre-integration complex [188], which is 
transported into the nucleus where the viral DNA is integrated with the host cell 
genome [175, 189]. After integration the virus can become latent and persist for the 
lifetime of the infected cell, making eradication of infection very difficult [190-192]. 
 
Starting from the 5’ long terminal repeat (LTR), host cell RNA polymerase II performs 
transcription from the integrated provirus. The initial RNA splice variants encode Tat, 
Rev, and Nef. Tat binds a secondary RNA structure, the transactivation response region 
(TAR) in the LTR greatly enhancing RNA synthesis through the phosphorylation of 
RNA polymerase II [193]. Nef appear to have several effects on host cell molecules, 
and is responsible for downregulation of host cell CD4, CD28, and MHC class I [175]. 
Nef has also been implicated in binding to p53, potentially affecting the protein half-
life, making the infected cells more resistant to apoptosis [194]. Rev is responsible for 
the shift to expression of late-phase structural proteins through the interaction with Rev 
responsive elements (RRE) in single-spliced and non-spliced transcribed mRNA. Rev 
acts as a transport molecule that is shuttling between the nucleus and the cytosol, 
mediating the transport of RRE-containing mRNA transcripts to the cytosol to allow 
their translation [195, 196]. Late stage transcripts include the polyprotein Gag p55 or 
Gag-Pol p160 and Env together with Vif, Vpu, and Vpr. 
 
Matrix, capsid, and nucleocapsid encoded by the Gag p55 polyprotein are responsible 
for virus particle assembly at the host cell membrane, while p6 is important in virion 
budding [197]. The budded virions contain un-processed Gag-Pol p160 and are 
immature and non-infectious until cleaved by the viral protease to indicated 
subcomponents (Figure 5). The accessory proteins Vif, Vpu, and Vpr were shown to 
have a wide array of effects [198-200]. Among the most studied is the mechanisms by 
which Vif counteract the host cell enzyme apolipoprotein B mRNA-editing enzyme-
catalytic polypeptide-like 3 (APOBEC3) [201, 202]. The APOBEC3 proteins belong to 
the same family as AID, responsible for Ab SHM (described in section 2.3.1). 
APOBEC3 proteins incorporate in virions upon budding and follow the virus to the 
next host cell. When the virus infects a new cell, APOBEC3 catalyzes C to U 
deamination on the negative strand transcripts in the reverse transcription process, 
leading to G-to-A transitions in the resulting positive strand DNA, with the potential of 
disrupting downstream gene products [203]. However, it has also been suggested that 
APOBEC3 deamination can contribute to viral diversity and insertion of drug-
resistance mutations [204]. Vif counteracts APOBEC3 by two mechanisms: interfering 
with its incorporation into virions by targeting it for ubiquitinylation and degradation, 
and reducing the translation of APOBEC3 mRNA [205, 206]. The effect of Vif is 
species specific [207], similar to another host innate restriction factor, Tripartite motif 
protein 5α (TRIM5α), which is also counteracted by HIV-1 in humans [208]. It is not 
entirely clear how TRIM5α exert its effects, but it contains a PRY/SPRY domain that 
can recognize incoming capsid structures and has been proposed to interfere in the 
uncoating of the virus and sequestration into cytoplasmic bodies targeted for 
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proteasomal degradation [209-211]. For more comprehensive reviews about APOBEC3 
and TRIM5α see [202] and [203]. 
 
4.3 THE ENVELOPE GLYCOPROTEINS 
The HIV-1 envelope glycoproteins (Env) are produced as a singly spliced mRNA from 
a larger RNA also containing Vif, Vpu, and Vpr. The Env mRNA contains an RRE 
(described above) enabling its transport from the nucleus to the rough endoplasmic 
reticulum (rER) where it is translated to an 88-kDa precursor protein, which is co-
translationally modified by the addition of N-linked glycans almost doubling the 
molecular weight to a 160-kDa glycoprotein referred to as gp160. In the ER the 
precursor protein forms multimers [212], which are proteolytically processed into gp41 
and gp120 in the post-ER/Golgi compartment by host cell furin [213]. Transport 
through the Golgi apparatus allows further modifications of the glycans into complex 
type N-linked sugars [214]. On the surface, the gp41-gp120 complex is expressed as 
non-covalently linked heterodimeric trimers [215, 216], the only virally encoded 
surface exposed proteins. It has been shown, biochemically and via cryo-electron 
tomography (cryo-EM), that there are only ~10 trimeric Env spikes per virion [217-
219]. Several host cell derived proteins are also found in the membrane of the budding 
virion and have been implicated in viral attachment to target cells [220, 221]. 
 
HIV-1 gp41 is responsible for anchoring Env in the cell/virus membrane. It contains a 
long cytoplasmic tail interacting with the matrix protein, a transmembrane domain, and 
a glycosylated ectodomain that is mostly shielded by gp120. HIV-1 gp120 is composed 
of five constant regions (C1-5) and five variable regions (V1-5) [222]. V1-4 contains 
conserved cysteines flanking the variable regions, enabling the formation of loop 
structures via disulphide linkage [223], which are exposed on the surface of gp120 and 
are highly immunogenic [224-226]. 
 
Extensive efforts have been made to obtain a crystal structure of the unliganded Env, 
but due to the gp41-gp120 instability, the inherent conformational flexibility and high 
density of glycans on gp120, such efforts have been unsuccessful. However, several 
structures were solved for the individual gp41 and gp120 subdomains. Structures of 
gp41 have enabled the identification of Env as a likely trimeric complex [216] while 
the six-helix bundle [227] shed light on the mechanism of virus-host cell membrane 
fusion. Structures of gp120 were obtained from trimmed and deglycosylated gp120 
core molecules unliganded and bound to soluble CD4 and/or MAbs [228-232]. These 
structures enabled the identification of an inner and outer domain of gp120 connected 
by a bridging sheet (Figure 6A). The inner domain faces the trimer axis and gp41, 
while the outer domain is more exposed on the surface of gp120. It is mainly the outer 
domain that is heavily glycosylated to create a “silent face” not easily recognized by the 
humoral immune system (Figure 6B) [185, 233]. Furthermore, with the identification of 
the gp120 “neutralizing face” the core structures have been instrumental in immunogen 
design efforts, reviewed in [234]. 
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Figure 6. Crystal structure of gp120 core shown in ribbon diagram (A) and surface rendering (B). (A) 
The division of gp120 core into the inner and outer domain separated by four beta strands forming the 
bridging sheet are indicated. Beta strands are shown in salmon and alpha helixes in red. The proximal 
arrow indicate direction toward the virus membrane and the distal arrow toward the host cell membrane, 
the same orientation is followed in (B), where the gp120 core is divided into three regions based on 
recognition of the immune system. The non-neutralizing face, directed toward the trimer axis, is shown in 
magenta. The heavily glycosylated silent face is shown in blue, and the CD4-binding neutralizing face is 
shown in grey. (A) was adapted from  [229] and (B) from [233]. Both figures were reproduced with 
permission from Nature Publishing Group. 
 
The unliganded structure obtained for HIV-1 gp120 core display the CD4-bound 
conformation [228], similarly observed in previous gp120 core structures crystallized in 
combination with ligands [229-232], indicating that the variable loops and gp41 deleted 
in the gp120 core stabilize Env in a native conformation, while their removal favors a 
CD4-bound conformation. However, as the CD4-bound conformation is not readily 
exposed on native spikes it will be necessary to obtain high resolution images of Env in 
its native state to inform immunogen design efforts. Attempts at using cryo-electron 
tomography to visualize unliganded surface bound HIV-1 Env have generated images 
with a resolution of ~10-30 Å. This is not enough to trace individual atoms and protein 
secondary structures, as with crystallization, but substantial shifts or subdomains in the 
Env structure are visualized [219, 235-239]. 
 
A recent effort to investigate the composition of the native HIV-1 Env was presented 
by Mao et al., where they used single particle cryo-EM to obtain a model of the native 
Env at high resolution [239]. They expressed cleavage-defective primary HIV-1 Env of 
the JR-FL strain, with a truncated cytoplasmic tail to increase surface expression [240]. 
The Env was solubilized from the cell membrane and flash frozen. More than 90,000 
images were acquired and merged to obtain a resolution of 10.8 Å. At this resolution 
Env has a tetrahedral appearance, with a large central cavity separating the protomers. 
Individual subdomains of Env were visible and five different domains could be 
identified (Figure 7). Interestingly a novel domain was observed that suggest 
interactions between the gp120 protomers. The domain was named the “gp120 trimer-
association domain” and encompasses a six-way junction between the protomers at the 
apex of the trimer. The contacts are most likely composed of the V1/2 and V3 loops, 
  19 
which extend inward toward the trimer axis in a highly structured manner. Further 
support for the importance of the V1/2 loop for trimer stability is shown when a single 
N-linked glycan deletion in the V/2 stem or V1/2 loop deletions enables CD4-
independent binding to CCR5 and infection of cells lacking CD4 but expressing CCR5 
[237, 238, 241]. 
 
Figure 7. Subdomains included in one HIV-1 Env protomer as determined by Mao et al.  Shown are the 
gp41 transmembrane domain (light blue), the g41 ectodomain (purple/green), the gp120 inner domain 
(gold), the outer domain (turquoise), and the gp120 trimer association domain (pink). The general area of 
the CD4 binding-site is circled in red. (A) Shows the trimer from the side/back. (B) Shows the trimer 
from the side/front. (C) Shows the trimer from the apex (from the view of the host membrane). The figure 
was adapted from [239] and reproduced with permission from Nature Publishing Group. 
 
The Mao et al., cryo-EM structure display high homology to a cryo-EM structure 
described by Liu et al., where native HIV-1 Env was evaluated in conjunction with 
CD4 and/or MAb-binding, similarly to the first crystallized gp120 core [229]. By fitting 
the gp120 core into native and post CD4 binding cryo-EM pictures, molecular models 
could be generated explaining the conformational changes observed. Liu et al. showed 
that CD4 binding causes an outward rotation of the individual gp120 subunits, exposing 
the CoRbs and extending the V3 loop, as previously proposed [230]. As the gp120 
subunits move away from each other, the bound CD4 and V1/V2 loop move away from 
the center of the spike, creating an open conformation, exposing the gp41 ectodomain, 
which can then interact with the host cell membrane to mediate fusion (Figure 8). 
Figure 8. Model describing conformational changes occurring in HIV-1 Env following CD4 binding. 
The viral membrane is indicated in grey, gp41 in blue, and gp120 in red. Following CD4 binding 
(yellow) the gp120 monomers rotate outwards, extending the V3 loop (green), and creating a more open 
conformation exposing the gp41 stalk. The figure was adapted from [235] and reproduced with 
permission from Nature Publishing Group. 
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4.4 HIV-1 ENV IMMUNE EVASION STRATEGIES 
HIV-1 uses several mechanisms to escape Ab-mediated neutralization and to induce 
Abs toward regions not exposed on the functional Env spike (reviewed in [234]). These 
mechanisms are mainly centered on variations in the envelope glycoproteins, which are 
made possible due to the high mutation rate of the HIV-1 genome and the structural 
plasticity of Env. Here are four major mechanisms described. 
 
4.4.1 Genetic variability 
The major challenge with controlling the HIV-1 epidemic is the genetic variability of 
the virus. Not only does it complicate vaccine design, but it is also puts severe demands 
on the human immune system to keep up with ongoing infections, as the antigens 
change faster than new immune responses can be elicited. The basis for the high 
genetic diversity of HIV-1 is the error-prone reverse transcriptase, which incorporates 
~0.2 mutations per genome and replication cycle [242, 243]. Coupled with a very high 
replication rate of ~1010 new virions per day in an infected individual [244], a large 
number of different viral variants are generated. A large proportion of the humoral 
immune responses elicited during infection is directed against the variable regions 
resulting in strain-specific neutralization. The variable regions can, however, readily 
change both in sequence and length to escape these Abs (Figure 9) [245-249]. 
 
Figure 9. HIV-1 escape from autologous 
neutralizing antibodies (Abs). When neutralizing 
Abs are generated escape variants are selected for. 
This is followed by new autologous neutralizing 
Abs recognizing the new HIV-1 variant, from which 
escape will occur again. This cycle will be repeated during the course of the infection. The figure was 
adapted from [250]. 
 
4.4.2 Exposure of non-native Env 
As described previously, gp160 is cleaved by the host enzyme furin to gp120 and gp41 
that are held together by non-covalent interactions to yield the native Env complex. 
However, non-native Env structures are also present on the surface of virions, as shown 
by isolation of virus particles with non-neutralizing Abs [251-253]. Furthermore, the 
ratio of non-infectious to infectious virus particles is high, potentially due to low 
expression of viable surface Env [254, 255]. The presence of different Env forms on 
infectious virus-like particles (VLPs) was studied by Moore et al. Using several 
complementary methods they observed both gp41 stumps, generated from gp41/gp120 
dissociation as indicated in figure 10, and gp41/gp120 monomers [256]. These non-
native Env structures are highly immunogenic, but they mainly generate non-
neutralizing Abs that do not cross-react with the native Env spike. These decoy 
immunogens have been proposed to divert the immune system, making the overall Ab 
response directed against irrelevant target epitopes [257-259]. 
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Figure 10. Elicitation of non-neutralizing 
antibodies toward free gp41 stumps and domains 
of gp120 not exposed on the functional spike. The 
figure was adapted from [250]. 
 
 
4.4.3 Conformational masking of Env surfaces 
Following CD4 binding, Env undergoes major conformational changes to form the co-
receptor binding site (CoRbs), which mediates the interaction with CCR5 or CXCR4 
[181, 183]. The co-receptor usage is highly conserved between HIV-1, HIV-2, and SIV 
[260, 261], suggesting an attractive target for Ab-mediated neutralization. However, 
despite abundant CoRbs-directed Abs elicited following HIV-1 infection and 
immunization with Env proteins, no broad neutralization was observed [262-264]. The 
CoRbs-directed Abs are generated in a CD4-restricted manner, where they are only 
elicited if there is a high-affinity functional interaction between Env and host cell CD4, 
as observed in humans and nonhuman primates, but not in e.g. rabbits and mice [112, 
264]. The lack of neutralization by this subset of Abs is potentially explained by steric 
restriction, where Abs fail to gain access to the CoRbs, which is formed after CD4 
binding when the Env spike is in close proximity to the host cell membrane [265] 
(Figure 11A). 
 
Figure 11. Conformational masking of the CoRbs (A) and via entropic masking (B). (A) The CoRbs of 
Env only forms after CD4 binding and is therefore inaccessible for circulating Abs. Following CD4 
binding, however, the antibodies have restricted access due to steric hindrance. (B) Env possesses a high 
degree of conformational flexibility impeding strong interaction with a large proportion of the Abs 
directed toward conserved regions. The figure was adapted from [250]. 
 
Another aspect of conformational masking has been proposed by Kwong et al. 
suggesting the existence of an entropic barrier the Abs have to overcome to bind Env 
stably [266], especially at the CD4-binding site (CD4bs) and CoRbs, which have the 
capacity to undergo substantial conformational changes [267] (Figure 11B). 
 
More recently it was shown that many of the non-neutralizing Abs elicited toward the 
CD4bs bind hydrophobic patches in the bridging sheet (described in section 4.3). This 
has been suggested to elicit substantial conformational changes that are not well 
tolerated in the context of the functional trimer, with structural clashes between the 
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binding Abs and protomers or between adjacent protomers, with escape from Ab 
binding as a result [268]. The moderately broadly neutralizing Ab IgGb12  binds the 
outer domain of Env (described in section 4.3), which only induce minor entropic 
changes, and can therefore bind efficiently to functional trimeric Env spikes and 
neutralize the virus. Another way around the entropic barrier, as suggested by Kwong 
et al. is Ab binding to more than one Env structure, and thereby increasing the binding 
avidity. This is however complicated by the low density of functional spikes present on 
the HIV-1 virion [217-219] and will not necessarily overcome the problem with 
structural clashes occurring from elicited conformational changes. 
 
4.4.4 Glycan masking and quaternary packing 
Due to the extremely high density of glycans (approximately half the molecular weight) 
on the outer surface of Env, large portions of the proteins are more or less inert to the 
immune system. This protection has been referred to as the “glycan shield” [248] and 
the area covered, the “silent face” [233]. It was early on, found that immune 
recognition of glycoproteins was affected by high density of glycans [269]. Since then 
it was shown that the sites for N-glycosylation (NXS/T) in Env shift readily to allow 
viral adaption to the host immune response [248, 270] (Figure 12). Addition or removal 
of glycans, together with insertions and deletions in the V1/2 region can affect the 
quaternary packing of the Env spike to further shield neutralizing determinants [271]. 
 
Figure 12. Following the appearance 
of autologous neutralizing antibodies, 
N-linked glycosylation sites in Env can 
be added or deleted to enable antibody 
escape by occlusion of the target 
epitope. Adapted from [250].  
 
4.5 HIV-1 TRANSMISSION AND ESTABLISHMENT OF INFECTION 
The most prevalent form of HIV-1 transmission, accounting for >95% of all cases, is 
via sexual contact, with the majority being from heterosexual transmissions. There are 
several factors influencing the transmission efficiency, such as viral load in the infected 
partner, presence of other sexually transmitted diseases, lesions in the mucosa, male 
circumcision, and type of sexual act [272-276]. The majority of the remaining 5% of 
transmission events is due to inoculations using contaminated needles or other minor 
routes of transmission, such as mother-to-child and contaminated blood products. 
Productive infection is thought to arise from as few as a single founder virus in many 
cases [277, 278] and it is almost exclusively CCR5-using viruses that establish 
infection [278]. The dependence on CCR5 as the co-receptor for the majority of 
transmission events is illustrated by the “resistant” phenotype expressed by people 
homozygous for the CCR5 Δ32 mutant [279, 280]. The mutant consists of a 32 bp 
deletion, which introduces a premature stop codon in the CCR5 gene, abolishing 
functional expression on the cell surface. People heterozygous for the Δ32 mutant 
display partial protection to infection and have a slower disease progression [281, 282]. 
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The mutation is mainly observed in Caucasians and is prevalent in ~10 % of the 
population. 
 
Upon entering the mucosa- (or gut-) associated lymphoid tissue (MALT) the virus 
infects and replicates to high levels in activated CCR5+ memory CD4 T cells [283-
287], which are the main MALT-resident T cells [283-285]. At peak viremia, as much 
as 80% of the MALT memory T cells can be infected or killed. A large proportion of 
the human memory T cells reside in the MALT and even after initiation of 
antiretroviral therapy and suppression of viremia the reconstitution of the memory T 
cell compartment is poor [288, 289]. Even more profoundly depleted following 
infection are CD4+ IL17-producing T helper (Th17) cells [290]. These cells have been 
implicated in gut homeostasis and production of microbial defensins, which are 
important for the maintenance of the mucosal barrier [291, 292], thus their removal has 
been linked to chronic immune activation observed following HIV-1 infection [293]. 
Chronic immune activation shows a strong correlation with HIV-1 disease progression 
and has been implicated as a major mechanism behind the pathogenicity of HIV-1 
infection [293] (Figure 13). SIV infection of its natural host (e.g. sooty mangabeys) 
cause a similar rapid and profound depletion of CD4+ T cells; however, infected 
monkeys do not develop chronic immune activation and do not progress to AIDS [294, 
295].  
 
Figure 13. HIV-1 replication 
(gray), CD4+ T cell counts in 
the periphery (blue) and 
mucosa (black), and immune 
activation (red) following 
HIV-1 infection. Originally 
printed in [296]. Reproduced 
with permission from 
Elsevier 
 
 
 
 
The earliest T cell-mediated response detected in infected individuals appear around the 
time of peak viremia [297] (reviewed in [298]). Up until this time the virus replicates in 
the absence of an adaptive immune responses, but escape mutants will be selected for 
rapidly as viremia decreases to set-point levels [299]. The magnitude of the viral load 
set-point, which is largely attributed to the effectiveness of the cytotoxic T lymphocytes 
(CTLs), is predictive of the time for disease progression to AIDS, with lower level 
indicating slower progression [300]. Disease progression is further affected by MHC 
class I, called human leukocyte antigen (HLA) for humans and (Mamu) for rhesus 
monkeys, expressed by the infected individual [301]. Some HLA types, such as HLA-
B*57, B*58, and B*27 are associated with improved control of viral replication in 
humans [302] and Mamu-B08, B13, and B17 in rhesus monkeys [303], due to their 
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capacity to present peptides from conserved epitope regions [304, 305]. After the 
decline to set-point the infected individual is often clinically asymptomatic, and so 
called clinical latency ensues. However, even during this period there is a high level of 
ongoing viral replication, resulting in the production of escape mutants. The control of 
viral replication during this period is attributed to both cellular and humoral responses 
[306-308]. The latency can last for several years, however, gradually the CD4+ T cell 
count drops and eventually upon reaching below 200 cells per µl blood, the infected 
individual usually reaches the clinical status of AIDS and becomes sensitive to 
opportunistic pathogens [309]. 
 
4.6 B CELL MEDIATED RESPONSES TO HIV-1 ENV 
4.6.1 The role of B cell responses in HIV-1 infection 
The initial B cell response to HIV-1 is observed in the form of immune complexes, as 
early as eight days after detectable viremia. These Abs are directed toward the gp41 
ectodomain of the surface envelope glycoproteins. It takes an additional two weeks 
before the appearance of Abs directed toward gp120 [310]. Autologous neutralizing 
Abs to HIV-1 are not detectable until months after infection [247, 248, 311, 312] and 
are generally strain-specific with limited breadth [313, 314]. However, upon elicitation 
they exert a significant selective pressure on the circulating virus [315] resulting in 
rapid generation of escape variants, as discussed in section 4.4, enabling continued high 
viral replication [316, 317].  
 
Abs that neutralizes a broader range of virus isolates are usually not detected until after 
several years of chronic infection [318-321]. However, up to 25% of infected 
individuals have been shown to produce moderate to broadly neutralizing antibodies 
(bNAbs) after more than two years of infection [318, 320, 322]. Among these a subset 
are exceptionally broad and can neutralize a large portion of the known HIV-1 strains 
[320, 323, 324]. Mikell et al. analyzed longitudinal samples following HIV-1 infection 
and observed that the cross-reactive neutralizing Abs mainly developed in individuals 
where the early Env-specific B cell response targeted epitopes on the functional spike, 
whereas individuals that did not develop cross-reactive Abs targeted epitopes on 
monomeric gp120. These findings have implications for vaccine-design where it might 
be beneficial to mimic the early response observed in individuals developing bNAbs 
[325]. A similar study by Lynch et al. analyzed longitudinal serum specificity toward 
the CD4bs (more specifically the RSC3 protein, indicative of broadly neutralizing 
reactivity), and showed that such Abs arose quite early after infection although the time 
of appearance was variable between donors (10-152 weeks). The titers were also low 
and up to three years were needed to expand enough to make a significant impact on 
plasma neutralization [326]. 
 
Selective adsorption followed by mapping of broadly neutralizing sera has shown that 
both the membrane-proximal region of gp41 and several regions on gp120 can be 
targeted, with frequent observation of glycan-dependent and CD4bs-directed 
neutralization [319, 321, 327-329]. It has further been shown that the neutralization can 
  25 
be mediated by relatively few specificities [329]. These findings provide proof-of-
concept that the immune system can elicit broad and potent Abs and give hope to the 
vaccine field, that such Abs can be elicited via immunization. Furthermore, if elicited in 
sufficient concentrations they are likely to protect the individual from infection or 
attenuate replication, as indicated by passive transfer studies of bNAbs in macaques 
followed by subsequent chimeric SIV/HIV (SHIV) challenge [330-334]. 
 
In addition to direct neutralization, anti-Env Abs mediate effector functions via the Fc 
portion of the Abs. Fc-mediated effects have been implicated both for neutralizing 
[330] and non-neutralizing Abs [335] in protecting monkeys from mucosal viral 
challenge. However, of non-neutralizing Abs, only those targeting gp41 were shown to 
have an effect, possibly due to the presence of gp41 stumps on viral membranes, while 
the non-neutralizing gp120-directed Abs recognize epitopes that are not exposed on 
infectious viruses [335]. Other gp41-directed Abs have been implicated in delayed 
HIV-1 disease progression by effectively activating NK cells [336]. 
 
4.6.2 Broadly neutralizing antibodies and their implication for vaccine design 
For more than 10 years only four broadly neutralizing Abs isolated from HIV-1 
infected individuals were known. IgGb12 targeting the CD4bs [337], 2F5 and 4E10 
targeting the membrane-proximal region of gp41 [338, 339], and 2G12 targeting high-
mannose glycans on gp120 [340]. Thanks to the application of several new 
technologies additional bNAbs have now been isolated, some of which identify new 
target epitopes on Env (reviewed in [145]). The techniques used for isolating the MAbs 
were either from hybridoma immortalization of memory B cells [341, 342], flow 
cytometric sort of antigen-specific B cells followed by single-cell RT-PCR and cloning 
[343-346], or screening of supernatants from stimulated memory B cells plated at low 
cell numbers per well (2-3 cells) for neutralizing activity followed by antibody cloning 
[347-350]. The flow cytometric sorting strategy uses well-defined baits to fish for 
specific reactivities, such as B cells directed toward the CD4bs [345, 346]. This 
approach, however, limits the type of broadly neutralizing reactivities that can be 
isolated, to previously known determinants. Unbiased screening of stimulated memory 
B cell cultures circumvents this problem, as shown by the discovery of novel broadly 
neutralizing reactivities toward trimer and glycan specific regions on Env [347, 348]. 
However, this method has the caveat that a large number of cells must be screened to 
find interesting targets. Another recently published method utilizes an approach where 
flow cytometric sorting is performed with transfected cells expressing Env on the 
surface. This method enables isolation of memory B cells reactive with the native Env 
spike [351]. This approach is based on previous findings showing that bNAb but not 
non-neutralizing Env-directed Abs bind cell surface-expressed Env, while both sets of 
Abs bind soluble Env antigen [352-354]. Although the method is less efficient than 
recombinant protein baits it has a higher likelihood of finding Abs neutralizing Env via 
novel epitopes [351]. 
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The new generation bNAbs display a vastly improved breadth and potency in 
comparison to the first generation MAbs and several groups have mapped how the Abs 
bind and neutralize Env to get an improved understanding of how they can circumvent 
the immune evasion strategies exhibited by Env [355-360]. 
 
To investigate how Abs evolve to become broadly neutralizing Wu et al. performed 
454 sequencing on PBMCs from the donor that the bNAbs VRC01 and VRC03 were 
isolated from [346] By using Ig family-specific primers for PCR amplification coupled 
with bioinformatic analysis of obtained sequences, thousands of related clones were 
identified allowing the Ab linage to be traced in the infected individual [357]. A similar 
approach was taken for the bNAbs PGT135-137 described by Walker et al. [348, 361]. 
The identification of different evolutionary variants of the bNAbs, together with an 
improved understanding of potential vaccine targets on the Env trimer, have 
implications for vaccine design as it may be possible to design antigens that selectively 
drive clones in the evolutionary chain in a desired direction (reviewed in [362, 363]). 
Additionally, the design of different antigens for sequential boosting may be a 
necessary to promote SHM as many of the infection-induced bNAbs display very high 
mutation rates (>15% of VH nucleotides), something that might be difficult to achieve 
with a single antigen [10, 139]. 
 
4.6.3 Immunization-elicited antibodies 
Since the identification of HIV-1 as the causative agent for AIDS numerous attempts 
were made to design an effective vaccine. Four candidates have made it to phase IIb/III 
clinical trials (described in section 4.6.3.1) and the results indicate that both T cell and 
B cell responses are necessary for a successful vaccine [364]. The Env antigens used 
were recombinant gp120 monomers, which in standardized pseudovirus assays [365, 
366] display limited neutralization breadth [72, 367]. Current preclinical vaccine 
candidates based on recombinant stabilized trimeric Env elicit improved breadth 
although at low levels and limited to few primary viruses [72, 368-371]. As a proof-of-
concept, however, Barnett et al. showed that immunization with recombinant trimeric 
Env could protect monkeys from challenge with homologous SIV-HIV chimeric virus 
(SHIV), providing evidence that parenteral immunizations can induce sufficient 
humoral responses to protect against mucosal challenge if the correct Ab specificities 
are generated [372]. 
 
The majority of Abs elicited following trimeric Env immunization are directed toward 
the variable loops [368, 373-375], limiting pseudovirus neutralization to mainly 
autologous or T cell lab-adapted virus strains. However, reactivities toward more 
conserved determinants, such as the CD4bs are also elicited [10, 112]. Following 
isolation and epitope mapping, a panel of CD4bs-directed MAbs were shown to 
resemble non-broadly neutralizing CD4bs-directed MAbs elicited during chronic HIV-
1 infection [10]. Fine mapping of the Ab binding footprint show that they bind Env in 
close proximity to the trimer axis (see section 4.3) often interacting with residues in the 
bridging sheet, possibly inducing conformational changes resulting in steric clashes as 
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described in section 4.4.3. In contrast, the broadly neutralizing MAb, VRC01, binds an 
overlapping footprint, but more distally on the gp120 outer domain, perhaps allowing 
better access of this type of Ab on the functional Env spike. As mentioned previously, 
attempts to focus vaccine-elicited immune responses on conserved and neutralization 
sensitive determinants [271, 376, 377] have met with limited success. However, there 
are some indications that stabilization of specific epitopes can generate enhanced 
antibody responses to these determinants [378], suggesting that such engineering 
efforts are promising for the future. 
 
A promising finding was recently published by McCoy et al., where they isolated a 
broadly neutralizing Ab, called J3, from a llama immunized with trimeric gp140 Env 
[379]. Llamas display both single heavy chain Abs (VHH) and heavy and light chain 
paired Abs (similar to humans). The expression of VHH Abs allows efficient 
evaluation of phagemid libraries where only the VHH repertoire is screened (no 
artificial IgH-IgL chain pairs has to be made) [380]. J3 was isolated by screening a 
phagemid library directly for neutralization without previous panning steps to 
recombinant protein. Interestingly the serum neutralization of the llama did not reflect 
the breadth and potency of J3 and based on the screening protocol the authors estimated 
that <0.012% of the total VHH repertoire are J3-like Abs, indicating that J3-like clones 
did not have a selective advantage following antigen boost, consistent with the 
observation that J3-binding to recombinant gp140 and gp120 protein in ELISA was 
similar or reduced to that observed for non-neutralizing VHH clones [380, 381]. This 
shows the importance of using a screening method where bNAbs can be separated from 
non-bNAbs. 
 
4.6.3.1 HIV-1 phase III clinical trials 
To date four phase IIb/III clinical efficacy trials were conducted. The first two trials, 
performed by the company Vaxgen were based on recombinant monomeric gp120 Env  
(AIDSVAX) given with alum adjuvant in seven consecutive doses in North America 
and the Netherlands (clade B) [382] or Thailand (clade B/E) [367]. The primary target 
groups were men who have sex with men (MSM) and women with high risk of HIV-1 
exposure or injection drug users. More than 7500 persons participated in the two 
studies and the HIV-1 incidence was 7% and 8.4% respectively in the placebo groups. 
No effect on HIV-1 acquisition [367, 382] or other immune parameters [383] was 
observed between the placebo and vaccine arms although all vaccine recipients 
developed high, but transient, Env-specific Ab responses, with limited breadth [384]. 
 
Due to the challenge of eliciting broadly neutralizing antibody responses, focus turned 
toward T cells as the main targets for a vaccine. Promising data showed that adenovirus 
vectors could protect monkeys from SHIV infection [385] and it was known that CTL 
responses were important for suppression of viremia in natural HIV-1 infection [301, 
386, 387]. A clinical study was initiated by Merck with a replication-defective 
adenovirus type 5 vector expressing the HIV-1 genes gag, pol, and nef of clade B [388]. 
The vaccine was given three times to 3000 participants. At a planned interim analysis it 
was found that the vaccine had no effect upon acquisition of infection or viral loads and 
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when evaluating vaccine-induced immunity it was also found that participants 
presenting high levels of adenovirus type 5-directed Abs upon study initiation and were 
un-circumcised exhibited an increased risk of HIV-1 infection in comparison to the 
placebo group [389]. The STEP trial findings were recently recapitulated in a 
nonhuman primate study where the monkeys had been made seropositive to Ad5 before 
immunization and challenge with SIVmac251. There was a trend toward enhanced 
infection in the Ad5 seropositive group compared with controls but the study was too 
low-powered to definitively determine if pre-existing adenovirus immunity could 
enhance acquisition of infection [390]. In another recent study, enhanced acquisition of 
infection to low dose challenge with SIVmac251 was correlated with high levels of 
SIV-specific interferon gamma producing cells in rhesus macaques immunized with 
DNA and VLPs [391]. These findings indicate a potential risk with the presence of 
large numbers of non-protective activated T cells at the time of infection. 
 
The fourth late phase clinical trial, called RV144, was based on a prime-boost regimen 
with the canary-pox vector (ALVAC) encoding a modified clade B/E Env and clade B 
gag/protease together with clade B/E gp120 protein monomers (AIDSVAX) [160, 
392]. The vaccine was given to more than 16 000 participants in Thailand and upon 
completion; vaccine efficacy was calculated to 31% in the modified intention-to-treat 
analysis, with the largest effect in low to medium risk groups [160]. In follow-up 
analyses, it was suggested that the presence of IgG Abs to the V2 loop correlated with 
reduced risk of infection [393] and that this effect was ablated if high levels of Env-
specific IgA was present [394]. Considering that the RV144 and Vaxgen trials used the 
same recombinant protein for immunizations, but had different outcomes (31% 
protection in RV144 and no protection in the AIDSVAX trial) it will be important to 
further define potential correlates of protection in RV144, as well as to repeat this 
vaccine concept in independent trials. 
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5 ANIMAL MODELS IN VACCINE RESEARCH 
Animal models are imperative for understanding human immunology and host response 
to infectious agents. They are frequently used as preclinical gatekeepers for vaccine 
candidates and they are needed for toxicity and pathogenesis studies. The immune 
system is a complex biological system that would be impossible to accurately 
recapitulate by in vitro models or in silico. However, when using animal models it is 
important to define confounding factors in the translation to human immunology. It is 
therefore of great interest to identify the model most suited to the question addressed. In 
this section I will mainly focus on the nonhuman primate models, the focus of this 
thesis. I will further briefly discuss additional models important for infectious disease 
research. 
 
5.1 NONHUMAN PRIMATE MODELS 
Nonhuman primates are divided into two groups: old-world monkeys, including 
baboons, macaques, gibbons, and great apes; and new-world monkeys, including 
capuchin, howler, and squirrel monkeys. It is mainly old-world monkeys that are used 
in HIV-1 research due to their similarity to humans and the existence of model viruses 
inducing disease resembling HIV-1 infection in humans. HIV-1 can only productively 
infect chimpanzees due to the host restriction factors APOBEC3 and TRIM5α 
(described in section 4.3), which limit infection if not countered by HIV-1-encoded 
proteins. Early in the field of HIV-1 research, chimpanzees were used for pathogenesis 
and vaccine studies [395-397]. However, due to ethical considerations, cost and the fact 
that they seldom develop AIDS after infection, the field has turned toward other models 
[398, 399]. 
 
Currently, the most prominent models for HIV-1 translational studies are Asian 
macaques (rhesus, cynomolgus, and pig-tail macaques), and especially rhesus monkeys 
(reviewed in [400]). They share a high level of homology to humans both in sequence 
(average 93% [9]), gene expression, [401] immune cell composition [402, 403], and 
responsiveness to stimulation with pathogen-associated danger signals [404, 405]. They 
can be efficiently infected with SIV and chimeric SIV/HIV viruses (SHIV) to evaluate 
pathogenicity and T cell-based vaccines as well as Ab-mediated vaccine protection, 
respectively. SIV infection recapitulates HIV-1 infection in humans well, and has 
provided much of the current knowledge regarding mucosal transmission [406], 
although disease progression to AIDS tends to be faster than observed for humans 
(reviewed in [400, 407]). Depending on the SIV isolate and the route of infection used 
for challenge, it is also possible to mimic conditions resembling natural infection in 
humans [408]. SHIVs were constructed specifically to enable the evaluation of Ab-
based vaccines in monkeys. The classical SHIVs contain the env, tat, vpu and rev genes 
from HIV-1 and the remaining genes, important to counter the host cell restriction 
factors from SIV (Figure 14). Additional SHIVs have been constructed, e.g. SIV 
containing only RT from HIV-1, to enable evaluation of RT inhibitor drugs [409] or 
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HIV-1 containing only SIV-vif, closely resembling native HIV-1 but with the caveat 
that it can only infect pigtail macaques efficiently due to their lack of TRIM5α (Vif 
counteracts APOBEC3) [410]. 
 
Figure 14.  Genetic organization of (a) HIV-1 (gray areas), (b) SIV (white areas), and (c) SHIV, where 
the SIV Env, tat, rev, and vpu has been exchanged for corresponding HIV-1 variants. Adapted from [411] 
and reproduced with permission from Elsevier. 
 
Initially, SHIVs using the CXCR4 co-receptor were constructed [412-418]. These 
viruses were after passage often very pathogenic and replicated well in macaques 
depleting peripheral but not gut CD4+ T cells [419]. However upon vaccination they 
were relatively easy to protect against [385, 420-422], raising concerns about whether 
CXCR4-using SHIVs are appropriate model viruses for HIV-1 challenge studies [423]. 
CCR5 using SHIVs were subsequently developed, initially only with HIV-1 clade B 
Env [424-426], but also more recently with Env from clade C [427-429]. The CCR5 
using SHIVs are considered to mimic natural HIV-1 infection better and different 
stocks that are more or less resistant to neutralizing Abs were generated [419, 430, 
431]. 
 
As with all models, there are caveats. This is also true for the rhesus macaque model 
and there are some differences that are important to consider (reviewed in [432]). For 
example rhesus macaques express a larger number of MHC class I and II alleles than 
humans and were shown to mount stronger T cell responses to experimental vaccines 
[432]. However, the result from the human STEP trial was recapitulated in macaques 
[390], indicating that the model is predictive under specific circumstances (here using 
an SIV challenge instead of a CXCR4 SHIV that initially indicated protective effect in 
immunized monkeys [385]). It was also recently shown that rhesus macaques likely 
express a larger number of Ab Ig genes compared to humans (Table I) [9, 10], although 
the effect of this is unknown. So far immunization of nonhuman primates with 
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recombinant proteins closely resembles responses in humans to similar antigens [367, 
433, 434]. Furthermore, MAbs isolated from HIV-1 Env immunized rhesus macaques 
display reactivities closely resembling those elicited during infection in humans, 
indicating that both species mount similar Ab responses [10]. This is further supported 
by the homologous V(D)J family usage profiles in human and rhesus B cell populations 
[10, 11, 13, 90, 435-439]. 
 
Another important difference, especially when evaluating Ab Fc-mediated effects, is 
the variability in Fcγ-receptors (FcγR). In a study by Warncke et al., they evaluated the 
FcγR in cynomolgus macaques and compared effector function and IgG subtype 
binding to the human counterparts [440]. They show that IgG1 (which is the most 
abundant circulating Fc subtype) have identical binding and effector function in both 
species (likely being highly predictive between the species), while IgG2 and IgG4 
display fundamental differences. In humans IgG2 and IgG4 display weak binding to 
FcγRs, while cynomolgus macaques show the opposite with strong binding. To balance 
the increased signaling the macaques instead express higher affinity between IgG2 and 
the inhibitory FcγRIIB, displaying an overall more reactive profile. 
 
5.2 OTHER MODELS 
Although several nonhuman primate species are used as models for HIV-1 
pathogenesis and vaccine evaluation, their usage is limited by cost, infrastructure, and 
availability. Also according to the three R’s (Refine, Reduce, Replace), higher order 
organisms should be replaced with lower order organisms or preferentially in vitro 
methods if possible. 
 
Due to the possibility to genetically and physiologically modify mice they have been 
adapted to become possible models for human disease. Several types of humanized 
mice have been generated and evaluated for how well they model the human immune 
system and how they respond to pathogen or vaccine challenge (reviewed in [441, 
442]). The models are generally based on three different approaches: (1) Mice are 
transgenic for one or more human genes, only allowing evaluation of very specific 
interactions, with the caveat that the system is highly artificial. (2) Immunodeficient 
mice grafted with human CD34+ progenitor cells. These mice produce human cells but 
due to the cells maturing in mouse tissues they display significant difference to the 
human counterparts. (3) Immunodeficient mice transplanted with human cells and 
tissues. One example is the BLT mouse that has transplanted human bone marrow, 
liver, and thymus to allow maturation of humanized cells in a humanized environment 
[443] Of these three types of humanized mice models, the BLT mice produce the most 
homologous immune system, with similar tissue distribution, receptor expression, and 
response to antigen or pathogen challenge, warranting further evaluation as a 
translational model [442].  
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6 MATERIALS AND METHODS 
In this section the major materials and methods used throughout the papers will be 
presented. For more detailed information, see papers I-IV. 
 
6.1 RECOMBINANT ENVELOPE GLYCOPROTEINS 
All proteins were produced via transient transfection of 293-F cell in serum free 
suspension cultures as previously described [264]. Briefly, cells were transfected at 1-
1.2×106 ml-1 using 293-Fectin and incubated for four days. Supernatants were harvested 
and cleared via centrifugation and filtration before the proteins were separated by 
affinity chromatography. The first separation was via surface glycan binding to lentil-
lectin coated beads. After extensive washing the proteins were eluted and captured via 
their His-tag in a second column containing nickel-chelated beads. Following further 
washing the proteins were eluted and the buffer was exchanged to PBS. Protein 
integrity and purity was assessed by SDS-PAGE. Protein probes for use in ELISpot 
analysis were biotinylated enzymatically on the C-terminal avitag [225]. All antigens 
used for immunizations were purified from LPS using Triton X-114 extraction prior to 
inoculation. 
 
The soluble, wildtype gp140-F constructs composed of gp120 and the ectodomain of 
gp41 were first described by Yang et al. [444]. They contain a C-terminal trimerization 
motif from the T4 bacteriophage fibritin stabilizing Env in a trimeric context. 
Furthermore, to eliminate gp120 dissociation from the soluble gp140-F trimers, a 
substitution mutation was introduced in the furin cleavage site. A number of variant 
Env proteins were also made as shown in figure 15 and described in [225]. All proteins 
contain a His-tag and the protein used as probes contain a sequence encoding the Avi-
tag at the C-terminus of the protein. 
 
Figure 15. Graphical representation of the Env glycoproteins used for immunization and as probes. (A) 
The gp140-F protein composed of gp120, the gp41 ectodomain, the fibritin domain (F), the His-tag (H), 
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and the Avitag. (B) Representation of a biotinylated, trimeric Env (gp140-F-bio) probe. (C) Trimeric Env 
probes lacking selected structural determinants for use in the subtractive B cell ELIspot analysis. The 
figure was modified from [225]. 
 
6.2 ANIMALS 
Macaques were immunized and sampled for papers I and II. No new animals were used 
in paper III and IV as samples from the animals described in paper I were used. In 
paper I, 12 female rhesus macaques and 4 cynomolgus macaques were included and in 
paper II, 6 female cynomolgus macaques were included. The macaques were kept in 
pairs in 4 m3 cages with enrichment according to general guidelines from the Swedish 
board of agriculture. All experiments were approved by the local ethical committee on 
animal experiments. Before initiation of the experiments all animals were habituated to 
the housing conditions for >6 weeks and confirmed negative for SIV, simian T 
lymphotropic virus, and simian retrovirus type D. 
 
6.3 IMMUNIZATIONS AND SAMPLING 
All immunizations were given with Abisco-100 and CpG ODN 2395 adjuvants. The 
total volume was divided in two halves, which were given in the quadriceps muscle, 
one half in each leg. In paper I, immunizations were given monthly while in paper II 
they were given at 0, 4, and 33 weeks. 
 
Immunizations and blood samplings were performed under sedation with 10 mg/kg 
ketamine (given i.m.). When sampled for mucosal lavages and bone marrow, animals 
were given an additional 0.5 mg/kg Xylazine (given i.m.) to induce muscle relaxation 
and analgesia. Blood was collected in 6-9 ml vacutainer tubes containing EDTA. Cells 
were isolated from blood and bone marrow through density gradient centrifugation with 
Ficoll-Hypaque. After red blood cell lysis and extensive washing with PBS the cells 
were frozen in fetal calf serum supplemented with 10% DMSO. Following sampling of 
mucosal surfaces, the lavages were added to a concentrated protease inhibitor cocktail, 
spun and the supernatant frozen at -80 °C. 
 
6.4 MEMORY B CELL STIMULATION AND ELISPOT ANALYSIS 
Memory B cells were differentiated to antibody-secreting cells (ASCs) by stimulating 
1×106 PBMCs for four days in 48-well plates with a cocktail composed of pokeweed 
mitogen (PWM), staphylococcus aureus cowan stain lysate (SAC), and CpG ODN 
10103. Following culture the cells were washed and transferred to ELISpot plates 
coated with anti-IgG and incubated over night. If bone marrow or peripheral plasma 
cells were enumerated they were plated directly on anti-IgG coated ELISpot plates 
without previous stimulation. After washing away the cells, antigen-specific IgG was 
detected by the addition of biotinylated Env probes (see section 6.1). Following the 
addition of streptavidin-ALP and BCIP/NBT, antigen-specific spots were formed 
where ASCs had produced Ab during the overnight incubation. Differential B cell 
  34 
analysis was performed as previously described to determine the frequency of memory 
B cells directed toward specific sub-determinants of Env [225]. 
 
6.5 FLOW CYTOMETRY 
In this thesis flow cytometry was used for two purposes: evaluation of the memory B 
cell stimulation protocol on B- and T cells in paper I (performed on a FACS-Calibur) 
and sorting single B cells in paper III and IV (performed on a FACS-Aria). 
 
To evaluate the stimulatory capacity of the cocktail on B- and T cells in paper I, 
PBMCs were labeled with CFSE before culture initiation. After six days of culture the 
cells were washed and additionally stained with MAbs for CD20 (B cells), CD27 
(activation/memory B cell marker), CD4 and CD8 (T cell markers). Proliferation was 
measured in B- and T cells as decrease in CFSE content. In another set of experiments 
PBMCs were stimulated for four days before staining with MAbs for CD20, CD4 and 
CD8, as well as for intracellular IgG. Intracellular staining requires permeabilization of 
the cells, and was therefore performed after the cell surface staining. All Ab staining 
incubations were performed in the dark for 20 min followed by washing with PBS 
supplemented with 2% FCS. 
 
In paper III and IV specific B cell subsets were sorted at single cell density into 96-well 
PCR plates based on their expression of CD27 (differentiate memory and naïve cells), 
surface IgG (indicate switched memory B cells), surface IgM (in conjunction with low 
CD27 indicate naïve cells) and Env probes (used only for the antigen-specific B cell 
sort performed in paper III). The cells were further stained to exclude T cells (CD3 and 
CD8), monocytes (CD14), and dead cells (Aqua blue or Grivid). The single cell 
lymphocyte population was identified based on (SSC-A vs FSC-A) and further removal 
of cell doublets based on (FSC-H vs FSC-A in paper III, and SSC-W vs SSC-H 
followed by FSC-W vs FSC-H in paper IV). Final populations sorted were: 
CD20+CD27+IgG+ memory B cells (paper III and IV), CD20+CD27-IgG-IgM+ naïve B 
cells (paper IV), CD20+CD27+IgG+gp140-F+ total Env-specific memory B cells (paper 
III), and CD20+CD27+IgG+gp140-F+gp140-F-D368R- CD4bs-specfic memory B cells 
(paper III). 
 
6.6 SINGLE-CELL ANTIBODY CLONING AND EXPRESSION 
Single-cell RT-PCR was used in papers III and IV with the only difference that the 
primer sets were different. In paper III we used previously published primers designed 
for the isolation of human Ig genes [343] while in paper IV we constructed our own 
primers adapted to the rhesus genome. We only cloned the RT-PCR generated 
sequences for Ab expression in paper III. 
 
RT-PCR was performed on single B cells directly sorted into 96-well PCR plates 
containing lysis buffer as described in section 6.5. In paper IV we show that the 
addition of carrier RNA in the lysis buffer helps recovery. Reverse transcription was 
performed with superscript III using random hexamers. Subsequent PCR was 
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performed in different plates for IgH, Igκ and Igλ, using 50 cycles for the outer primers 
followed by nested PCR with inner primers for another 50 cycles. Positive 
amplification was determined with 96-well gels prestained with EtBr or Sybr Safe. The 
5’ primers consist of mixes covering the V-segment families while the 3’ primes are 
located in the Ab constant regions. A major difference between the primer sets used for 
paper III and IV is that the new rhesus 5’ primers are relocalized further upstream into 
the leader sequence (see section 2.2), which is less exposed to SHM and should stay 
relatively constant even in very mutated B cells. 
 
Positive wells from the nested PCR were sent for sequencing to determine V(D)J 
usage. Cloning primers containing restriction enzyme motifs were then matched to the 
obtained sequences and were used in a third high fidelity PCR starting from material 
from the nested PCR. PCR products were enzymatically digested and ligated into 
expression vectors containing Ab constant regions. Following transformation of 
bacteria, colonies were screened for positive inserts, which were sent for sequencing to 
verify the original sequence obtained after the nested PCR. If the sequence was 
consistent, the matching IgH and IgL chain vectors were co-transfected into 293-F cells 
using Freestyle MAX reagent. On day four of transfection the supernatants were 
evaluated for Ab production and Env-binding by ELISA. Successful Ab production 
was verified through coating with anti-IgG and antigen-specific Abs through coating 
with different forms of Env. CD4bs reactivity was determined as reduced/abrogated 
binding to the gp140-F-D368R mutant in comparison to wildtype gp140-F protein. If 
the cultures were positive for IgG and Env binding they were kept an additional 1-3 
days (5-7 days total) after which the Abs were purified. 
 
Ab purification was performed by incubating the cleared supernatant (centrifuged and 
passed through a 0.22 µm nylon mesh) with protein-G coated beads for 2h. The beads 
were then extensively washed before the Abs were eluted with low pH buffer. 
Following neutralization the buffer was exchanged for PBS by centrifugation using 30 
kDa cut-off centricons. Finally, the Ab concentration was measured by nanodrop and 
purity was assessed by SDS-PAGE. The specificity and function of the isolated Abs 
were evaluated by multiple assays as described in paper III. 
 
6.7 PSEUDOVIRUS NEUTRALIZATION ASSAY 
Pseudovirus neutralization assays were used in papers I-III to evaluate neutralizing 
properties of vaccine-induced plasma or isolated MAbs [365]. In this assay, the 
capacity of Abs to block infection of the TZM-bl reporter cell line by HIV-1 Env 
pseudotyped virus particles is assessed. The TZM-bl cells contain a luciferase reporter 
gene under transcriptional control of the HIV-1 LTR (see section 4.2). They are also 
stably transfected with the CD4, CCR5 and CXCR4 surface receptors allowing 
infection by the vast majority of HIV-1 viruses. Following infection and integration the 
pseudovirus drives the expression of the luciferase gene via production of Tat. The 
pseudoviruses are generated by co-transfection of 293T cells with a plasmid encoding 
the HIV-1 Env of interest, and another plasmid encoding the HIV-1 gag-pol backbone. 
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The resulting pseudovirus is replication-deficient as it lacks the env and rev in the 
genome. By pre-incubating the pseudovirus with plasma or MAbs in a dilution series a 
curve is generated indicating concentration Ab needed to inhibit virus infection. 
Commonly the titer/concentration necessary to inhibit 50% (ID50 or IC50 respectively) 
of infections is shown. 
 
To standardize and categorize the pseudoviruses they were divided into Tiers 
depending on how difficult they are to neutralize, as determined by well characterized, 
MAbs and the IgG fractions of plasma or serum from HIV-1 infected individuals [365, 
366]. Tier 1 viruses are divided into A and B, where both represent easy-to-neutralize 
viruses with 1A more so than 1B. Tier 1 viruses generally have more open 
conformation associated with lab-adapted strains. Tier 2 viruses are more difficult to 
neutralize and represent primary circulating HIV-1 strains. Neutralization against tier 2 
viruses is occasionally observed in vaccine studies, but then usually at high plasma 
concentrations. Tier 3 viruses represent very-difficult-to-neutralize primary viruses and 
are not commonly included in neutralization panels to evaluate vaccine-induced 
responses. 
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7 RESULTS AND DISCUSSION 
Much of the knowledge about B cell responses to HIV-1 Env is derived from 
serological studies, in particular from small animal models such as mice, rabbits and 
guinea pigs. However, macaques are also used extensively as preclinical models in 
HIV-1 vaccine research, but up until this thesis was initiated they were primarily used 
to evaluate different vaccine modalities in virus challenge experiments. In some cases 
circulating Ab responses were also evaluated, but there was little focus on the Env-
specific B cells themselves, the cells that are the bases for humoral immune responses. 
This was in part because reliable methods to study macaque B cell responses were 
lacking. In this thesis several new methods that facilitate studies of humoral immune 
responses in rhesus macaques were developed. This thesis also provides new 
knowledge about the rhesus macaque Ig locus enabling the evaluation of B cell 
responses at the genetic level. Here, these methods have been used to characterize 
LLPC and MBC responses following immunization with recombinant HIV-1 Env 
trimers and to characterize the properties of vaccine-induced monoclonal Abs directed 
against the conserved CD4 binding-site of Env. In this section, the results from papers 
I-IV are presented and discussed 
 
7.1 GENETIC EVALUATION OF RHESUS MACAQUES AS MODELS FOR 
B CELL RESEPONSES 
With the overall high sequence homology between rhesus macaques and humans, as 
well as phenotypic conservation of many immune cell subsets, macaques represent an 
excellent preclinical model for vaccine studies (see section 5.1). In an effort to refine 
the model and gain an improved understanding of Ab-mediated B cell responses, we 
characterized the immunoglobulin (Ig) loci of a previously published and assembled 
female Indian rhesus macaque genome [9] in paper III. We used previously published 
rhesus germline Ig genes [11, 445-447] in addition to bioinformatics tools [448] and 
sequences generated in our own lab to search the rhesus genome for Ig genes. We 
localized the IgH locus to chromosome 7, the Igκ locus to chromosome 13 and the Igλ 
locus to chromosome 10. Additionally we extracted V(D)J sequences likely 
corresponding to Ig gene open-reading frames (ORFs) (Table I). An intact ORF was 
defined based on the presence of an intact leader sequence and the absence of stop 
codons in the coding regions. Although the number of proposed Ig gene segments was 
larger in the rhesus macaque genome compared to in humans, the chromosomal 
organization was similar and the sequence homology was high (close to the average 
93% genome homology between human and rhesus). Additionally when performing 
joint sequence analysis between the human and rhesus V-segments they group 
according to gene family, rather than species, indicating a high conservation of the Ig 
loci (Figure 16). 
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Figure 16. Joined align between rhesus (red) and human (blue) V-segments. Numbers indicates gene 
family. The figure is adapted from paper IV and reproduced with permission from Elsevier. 
 
In addition to high Ig sequence homology and genetic structure of the heavy and light 
chain loci, the expression of Ab V(D)J gene families is also similar in sorted IgG+ 
MBCs between rhesus [10, 13] and humans [90] indicating that both species utilize 
their Ab repertoires similarly. Collectively, these results support the use of rhesus 
macaques as a model for human B cell biology. 
 
7.2 ASSAYS FOR THE EVALUATION OF B CELL RESPONSES IN 
MACAQUES 
7.2.1 Memory B cell differentiation 
Due to the quiescent nature of memory B cells (MBCs) it is difficult to quantitatively 
and qualitatively evaluate the compartment in their native state, however, an inherent 
effect of MBCs is that they readily differentiate to Ab-secreting cells (ASCs) upon 
stimulation. This property can be used to quantify antigen-specific memory B cells as 
ASCs are readily enumerated by ELISpot analysis. In paper I we established a 
protocol for macaque MBCs differentiation into ASCs, which we then used to analyze 
Env-specific responses following immunizations in paper I and II (Figure 17). 
 
 
Figure 17. Memory B cells (MBCs) and plasma cells (PC) were enumerated from peripheral blood via 
ELISpot analysis (A). (B) PBMCs were stimulated for 4 days to allow proliferation and differentiation to 
Ab-secreting cells (ASC), which were detected via ELISpot. PCs were detected through direct addition of 
the cells to ELISpot plates without previous stimulation. Representative ELISpot wells are shown before 
immunization (prebleed), and 1 and 2 weeks after immunization. No antigen-specific PCs were detected 
in prebleeds and at 2 weeks following immunization. 
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We evaluated several cytokines and mitogens that had been implicated in MBC 
differentiation based on previous publications for the human system. The combinations 
included Pokeweed mitogen (PWM) with the TLR9-ligand CpG and Staphylococcus 
aureus cowan strain lysate (SAC) [449], IL-21 with CD40-ligand [450], and IL-2 with 
IL-10 and CD40-ligand, or in combinations with IL-6 [451, 452]. We added CpG B or 
C to all stimulations, as TLR9-ligands were shown to drive human B cell 
differentiation efficiently, especially for MBCs ([453, 454] and unpublished 
observations). CpG was slightly less effective at driving rhesus B cell differentiation, 
although there is still a marked positive effect [405]. The stimulations were evaluated 
on cynomolgus and/or rhesus macaque cells depending on availability. Of the different 
combinations tested, two stood out as very potent: the PMW+SAC+CpG combination 
and the IL-21+CD40-ligand+CpG combination, both which promoted MBC 
differentiation into ASCs similarly with peak numbers of IgG-producing ASCs 
obtained after 3-4 days of culture (Figure 18). 
 
Figure 18. PBMCs were stimulation with 
indicated combination for 3-4 days followed 
by enumeration of IgG Ab-secreting cells 
(ASC) via ELISpot. 
 
 
 
 
While comparable results were obtained with these two combinations, we decided to 
use PWM+SAC+CpG for several reasons; first, because we had previously observed 
variability in the CD40-L stimulations when reagents were purchased from different 
vendors; second, because the IL-21+CD40-L+CpG mix was more expensive; and third, 
because of reports suggesting that IL-21 with CD40-ligand also drive naïve B cell 
differentiation, which could potentially act as a confounding factor in the assays [450]. 
 
To further understand how the PWM+SAC+CpG stimulation exerted its effect we 
stained PBMCs with CFSE and cultured them for six days. We observed a high level of 
proliferation in B cells, but also in T cells. To determine if the T cells had a role in the 
stimulation we sorted both rhesus and human B cells and T cells and stimulated B cells 
only or B cell/T cell co-cultures. IgG production from the PWM+SAC+CpG 
stimulation was almost exclusively detected in the B cell/T cell co-cultures, clearly 
indicating the dependence of the stimulation on the presence of T cells. CpG alone 
promote some Ab production even in the absence of T cells, although at a much lower 
level compared to the T cell dependent stimulations including PWM. 
 
7.2.2 Bone marrow culture 
As described in section 2.5 a large proportion of long-lived plasma cells (LLPC) reside 
in survival niches in the bone marrow, where they are dependent on close contact with 
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stromal cells. The LLPCs are responsible for producing high-affinity Abs that provide a 
first line of defense to invading pathogens by blocking infection or reducing the 
infectious dose, attenuating the infection [455]. The LLPC-dependent Ab production 
can be sustained for the life of an individual, although different antigens seem to induce 
different half-lives of the response by mechanisms not yet understood [77]. These 
qualities show how important it is to obtain an improved understanding of the B cell 
responses elicited through immunizations. Following Env inoculations we collected 
bone marrow biopsies at different time points to enumerate LLPCs by ELISpot analysis 
(Figure 19A). As observed in figure 19B top panel, the antigen-specific LLPC counts 
are low even when plating large numbers of cells (plated 1×106 cells). To see if we 
could increase the sensitivity of the assay, we cultured bone marrow in complete media 
for 1-3 weeks (Figure 19B lower panel) followed by antigen-specific ELISA. In the 
culture wells we observed the formation of stromal networks, likely supporting the 
survival of the LLPCs. Addition of exogenous IL-6 or APRIL, which were implicated 
for in vitro survival of LLPCs, did not increase the amount of Ab produced. The major 
limiting factor in observing a positive ELISA signal appears to be the amount of cells 
cultured. Bone marrow ELISpot was used in both paper I and II, while the bone 
marrow culture method was used in paper II. 
 
 
Figure 19. Schematic of quantification of bone marrow PCs. (A) Bone marrow was aspirated and the 
mononuclear cell fraction purified and frozen. (B) Top panel; long-lived PCs (LLPC) were enumerated 
via ELISpot by plating without previous culture. Shown are representative wells for Env-specific IgG-
producing PCs. Bottom panel; Bone marrow was culture for 1-3 weeks in complete media and thereafter 
the supernatant was measured for Ab secretion. Shown is Env-specific IgG at indicated time points (n=2-
4 donors). (w) indicates weeks following immunization. 
 
7.2.3 Flow cytometric single memory B cell sort and Ab cloning 
To gain an improved insight in the type of Abs that are elicited following 
immunization, in paper III we adapted previously published protocols for flow 
cytometric staining of antigen-specific MBCs followed by subsequent Ab cloning [343, 
344, 346]. IgG+ MBCs were sorted at single-cell density into PCR plates. The RNA 
was reversed transcribed and the V(D)J families amplified by nested PCR using mixes 
of primers covering the different Ab gene families. Following sequence verification the 
products were cloned into Ab expression vectors via restriction sites introduced by an 
additional PCR with cloning primers [2]. The primers used in paper III were based on 
human Ab sequences and had low efficiency for amplification of especially the kappa 
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and lambda light chains. In paper IV we therefore designed new primers based on the 
rhesus macaque germline sequences described in paper III, an additional two IgHV 
sequences we found during the work with paper IV and previously described rhesus Ig 
sequences [11, 14, 456, 457] (Figure 20). 
 
Figure 20. Workflow for the isolation of MAbs from sorted single cells. (A) The cells of interest were 
sorted at single cell density via flow cytometry into 96-well PCR plates containing lysis buffer. Reverse 
transcription was performed with random hexamers. Shown in the FACS plot is a gate for 
(CD20+)CD27+IgG+ memory B cells. (B) In paper IV the 5’ primers used in the 1st PCR were named the 
L1-primers since they anneal to the beginning of leader 1 (L1). In the 2nd PCR the 5’ primes were 
designed to anneal to the L1/L2 junction, to specifically amplify rearranged transcribed sequences. The 
primers were named the SE-primers. Following successful nested PCR the products were sequenced. 
Cloning primers were chosen depending on the V- and J-segment and run in a third PCR introducing 
restriction sites. (C) Products from the cloning PCR were digested with restriction enzymes and cloned 
into CMV-driven Ab expression vectors already containing a leader sequence and a constant region. 
After verification of vector insert, the Abs were produced via transient transfection of 293-F cells.  
 
The 3’ primes were located in the Ab constant regions, which are relatively conserved, 
making the design fairly easy. For the human 5’ primers, however, they were located 
mainly in the V-region FR1 [343]. In addition to imprinting the PCR fragment with the 
primer sequence and thereby affecting SHM calculations the V-region is exposed to 
SHM. This makes the primer set vulnerable to extensive SHM, commonly observed in 
the broadly neutralizing Abs isolated to date [145]. A problem that is solved when the 
primers are moved to the Ab leader sequence as shown by Scheid et al. [345]. 
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The Ab leader sequence constitutes two exons (L1 and L2) separated by a short intron 
(Figure 1) [24]. In the mRNA the intron is excised and the joined L1/L2 leader 
sequence functions as a signal peptide directing the mRNA to the rER where it is 
removed upon translocation of the nascent polypeptide into the ER. Each V-segment 
(IgH, Igκ, and Igλ) has a leader sequence upstream in the DNA and although relatively 
conserved there is some variation (usually <20%) within each gene family. Therefore 
the larger families commonly need more than one primer to enable amplification of all 
variants. 
 
Due to the reasons described above we decided to design the rhesus-specific 5’ primers 
so that they align to the leader sequence. A first nested primer set was generated to the 
most conserved regions within the Ig leaders. Designing primers toward conserved 
regions enabled a smaller number of primers to cover all variants, which usually 
improves the PCR, however, when testing the primer mixes on cDNA and single-cells 
the amplification was very poor. Further design and evaluation showed that it was 
important to place the primers in the beginning of L1 and also in the junction between 
the L1 and L2 exons (Figure 20). Since the RT-PCR is performed on single cells, both 
DNA and RNA is present, therefore using primers toward the L1 and L2 junction will 
allow specific amplification of mRNA with recombined V(D)J sequences. Additionally 
placing the primers in the beginning of the leader sequence indicates that the 
downstream sequence potentially forms secondary structures inhibiting efficient primer 
binding. 
 
The final 5’ primer sets consisted of 25 IgHV primers (11 outer and 14 inner), 18 IgκV 
primers (9 outer and 9 inner), and 21 IgλV primers (11 outer and 10 inner). The IgH 5’ 
primers can be paired with 3’ primers specific for IgG, IgA, IgD, or IgM. Additionally 
cloning primers containing restriction sites were designed for all rhesus germline V and 
J genes described in paper III and IV. However, since the Ab sequences are exposed 
to SHM additional cloning primers have to be generated to accommodate specific 
mutations. 
 
7.3 MAGNITUDE AND DURABILITY OF B CELL RESPONSES TO 
ENVELOPE GLYCOPROTEINS 
As discussed in section 3.1 and 3.4 an increasing number of licensed vaccines and 
vaccine candidates are based on recombinant proteins. However, the successful HBV 
and HPV vaccines are based on mutimeric VLPs while HIV-1 Env is based on soluble 
trimeric protein that additionally is heavily glycosylated. The high amount of glycans 
was shown to enable interaction with lectin receptors on APCs and exert downstream 
signaling effects [458]. Additionally Env binding to CD4 and or the co-receptors CCR5 
and CXCR4 may induce immunomodulatory functions in T cells, as suggested by in 
vitro studies [459-461]. All these properties potentially affect immune responses to Env 
following immunization [462], and several studies have indicated that the responses 
induced are relatively short-lived [146, 463, 464], suggesting that perhaps HIV-1 Env is 
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an intrinsically poor antigen [462]. In papers I and II we evaluated humoral and 
cellular B cell responses following immunization with trimeric HIV-1 Env (paper I and 
II) and Influenza HA (paper II) in Abisco-100 and CpG adjuvant. In paper I we 
immunized the macaques monthly five times while in paper II the macaques were 
immunized three times, with a long interval between the second and third immunization 
to allow evaluation of longitudinal responses (Figure 21). 
 
 
Figure 21. Immunization schedules and samplings for paper I and II. In paper I, rhesus macaqeus (n=12, 
6 receiving trimeric Env and 6 adjuvant controls) were immunized monthly five times. In paper II, 
cynomolgus macaques (n=6) were immunized three times, at 0, 4, and 33 weeks. Blood samplings are 
indicated by red arrows, bone marrow samplings by blue arrows, mucosal samplings by green arrows, 
and immunizations by black arrows. Numbers above the arrows indicate week of immunization or for the 
orange arrow, SHIV challenge. 
 
For both studies, peak Ab titers were reached after two immunizations and subsequent 
boosting did not elevate the titers further. A similar profile was observed in the MBC 
compartment, with peak frequencies of 10-20% of the total IgG+ MBCs being specific 
for Env. The circulating PC compartment reached similar frequencies as the MBCs, 
although they only produced very transient peaks of ASCs at 1 week following boost 
and were undetectable at 2 weeks. This is consistent with rapid differentiation of MBCs 
to ASCs upon antigen challenge. These results are also consistent with observations 
following immunization with influenza [73], and rabies vaccines [74], and following 
dengue virus infection [465] suggesting that peak Env responses elicited from 
immunizations appear to be within a normal range of those elicited by protective 
vaccines or following infection. Additionally, we detected Env-specific LLPCs in the 
bone marrow of immunized macaques, indicating that long-lived responses were likely 
induced, although similarly to the other B cell compartments, maximum frequencies 
were also reached following the second immunization and were not boosted further. 
 
In paper II we evaluated the longevity of B cell responses following immunization. 
We compared Env responses to those of recombinant influenza HA, a soluble protein 
antigen that is not as glycosylated and does not interact with T cells. We produced HA 
in the same expression system as Env to allow a direct comparison of the responses 
against these antigens. Longitudinal responses were evaluated for 29 weeks following 
the second immunization, when peak B cell responses were reached. HA responses 
were slightly lower than Env responses, possibly because HA is a smaller antigen. 
However, there were similar frequencies of antigen-specific LLPCs in the bone marrow 
for both antigens, perhaps indicating differential requirements for entering the bone 
marrow niche. Following peak responses, plasma Ab titers and MBC levels rapidly 
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contracted with a half-life of ~2 weeks, while the LLPC frequencies remained constant. 
The peripheral Ab responses were highly correlated with the mucosal Ab levels, 
indicating that the Abs detected at the mucosal surfaces result from transcytosis of 
circulating Abs [466], a mechanism that was shown to afford protection in HPV 
vaccinated women [467]. After 5-6 months, the Env and HA Ab titers reached a plateau 
~1.5 log lower than peak Ab titers, while the MBC frequencies declined further 
indicating that the Ab levels at the plateau levels were likely disconnected from the 
MBC compartment. Instead the frequency of antigen-specific Abs and LLPCs were at a 
similar level (~1% of total IgG responses) indicating that the LLPCs were responsible 
for maintaining the circulating Ab titers at this time as also suggested for other vaccines 
[76]. 
 
In comparison to the responses elicited by the soluble Env trimers in macaques, a 
previous study in humans using monomeric HIV-1 Env in the MF59 adjuvant required 
three inoculations to reach peak titers [468]. This was followed by a similarly rapid 
decline of Ab responses before reaching a less steep curve where the Ab waning was 
considerably slower for up to 200 days. In contrast, following immunization with the 
VLP-based HPV vaccine, there is a ~1 log decline in Ab titers over 30 months, after 
which the titers stabilize above baseline and are protective for >5 years [469]. 
Therefore, it is possible that soluble proteins in general elicit responses that decline 
rapidly, while this is different for particle-based vaccines. Collectively papers I and II 
indicate that soluble HIV-1 Env trimers induce B cell responses of similar magnitude 
and durability as other viral antigens suggesting that it is not an intrinsically poor 
antigen, at least not in the context of a strong adjuvant, as used in these studies. 
 
7.4 QUALITY OF B CELL RESPONSES FOLLOWING HIV-1 ENV 
IMMUNIZATION 
To gain an improved understanding of why current HIV-1 vaccine candidates are not 
eliciting protective responses to HIV-1 it is necessary to dissect the quality of the 
elicited B cell responses at higher resolution. Thanks to the development of several new 
methods this can be achieved at different levels for both cellular and humoral B cell 
responses. [225, 327] and [paper I, III, and IV]. 
 
In paper I we used a differential ELISpot [225] together with the MBC stimulation 
protocol to determine how Env region-specific MBC responses evolved following 
sequential immunizations. We observed a shift from early gp41-specific MBCs to more 
variable region-specific responses during the course of the study although a substantial 
portion of the response was directed toward non-gp41 and non-V1-3 regions. The 
observation that gp41-directed responses were prominent in early immunizations is 
similar to kinetics following infection, where gp41-specific responses are commonly 
detected before gp120-specific responses [310], although the reason for this is not clear. 
We also tried to use the differential probes to determine Env-specificities in the plasma 
and MBC culture supernatants of the immunized macaques. However, 
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reactivities observed were to the V1-3 loops, likely explained by a selective advantage 
of these Abs in the ELISA format competing out the other reactivities.  
 
To evaluate the functional properties of the Ab responses, neutralization of a panel of 
tier 1 and 2 pseudoviruses was performed. There was a clear improvement in 
neutralization to the panel between the second and fifth immunization, which was 
interesting considering that the overall Env-specific Ab titers were the same at these 
two time points, as described in section 7.3. As an indicator of Ab maturation we 
measured the avidity index of the plasma Abs. The avidity index is determined by 
comparing Ab bound to antigen before and after incubating with a chaotropic agent 
[470]. The more Ab bound, the higher the index, with 100% indicating no displacement 
of Abs. In paper I there was a significant increase in the avidity index during the 
immunization schedule potentially signifying an increased affinity, translating into 
improved neutralization in the pseudovirus assay. However, to formally show that this 
occurs for individual B cells, antigen-specific cells would have to be sorted and MAbs 
isolated for analysis of SHM and neutralization. Interestingly, when performing the 
avidity assay on the plasma in paper II, a similar increase in avidity index was 
observed during the extended interval between the second and third immunization, 
suggesting ongoing Ab maturation in the absence of booster immunizations, potentially 
due to persisting antigen and ongoing GC reactions (Figure 22) [471, 472]. In future 
studies it would be valuable to determine if the week 29 Abs (just before immunization 
three) in paper II are of similar quality as those elicited from five immunizations in 
paper I, as that would be informative for immunization schedules in future clinical 
studies using recombinant Env protein. Additionally, immunization schedules including 
long intervals improved the magnitude of longitudinal responses in other studies [468, 
473]. 
 
Figure 22. Ab maturation in paper I (open 
circles) and II (filled circles) as measured by 
avidity index. Arrows indicate immunizations.  
The Y-axis show folds increase in avidity index 
to following immunization 2 + 2 weeks. The X-
axis shows weeks since study initiation. 
 
  
 
 
Although neutralization assays and Ab mapping provide valuable information 
regarding the immunogenicity of candidate vaccines, fine details regarding how elicited 
Abs react with the antigen requires studies of MAbs. The identification of broadly 
reactive Abs in the plasma of individuals chronically infected with HIV-1 [474] and the 
subsequent isolation of multiple bNAbs from such individuals [145] has clearly shown 
that the human immune system is capable of eliciting Abs to HIV-1 that can target 
highly conserved epitopes and mediate neutralization against diverse HIV-1 variants. 
Several of the isolated bNAbs target the Env CD4bs [337, 345, 346], a region that only 
  46 
tolerates limited variability to retain the capacity to bind human CD4. However, all 
CD4bs-directed Abs are not broadly neutralizing and even MAbs with largely 
overlapping epitopes, such as IgGb12 and IgGb13 can display very different breadth 
and potency in neutralization assays [268]. 
 
It was previously shown that CD4bs-directed Abs are elicited by trimeric Env 
immunization of rhesus macaques [112]; however, the plasma neutralization breadth 
was limited indicating that the Abs were mostly strain-specific or targeting regions not 
exposed on the functional Env spike. In paper III we sorted MBCs targeting the 
CD4bs elicited using samples described in paper I. The aim was to gain an improved 
understanding of the types of CD4bs-directed Abs elicited by immunization and to 
investigate how they compare to CD4bs-elicited MAbs from chronically HIV-1 
infected individuals to inform future Env immunogen design efforts. 
 
CD4bs-directed MBCs were sorted using two differential probes, gp140-F (wildtype) 
and gp140-F-D368R (CD4bs-defective) conjugated to different fluorochromes. The 
D368R mutant abrogates binding by most known CD4bs-directed MAbs while 
retaining binding to MAbs targeting epitopes outside of the CD4bs. IgG+ MBCs 
binding to gp140-F but not gp140-F-D368R were defined as CD4bs-specific and were 
sorted at single cell density into 96-well PCR plates. The Ab IgH and IgL V(D)J gene 
segments were amplified by nested RT-PCR using a primer set designed for human 
V(D)J amplification [343]. PCR reactions giving products of the correct size were 
sequenced and products encoding IgH and IgL chains derived from the same single cell 
were independently cloned into expression vectors containing a leader sequence and 
constant region for the heavy and light chains, respectively. Functional Abs were 
produced via transient transfection of 293-F cells and tested for binding and specificity 
by ELISA. A panel of eight MAbs Abs specific for the CD4bs was isolated. One MAb 
(GE147) bound recombinant Env strongly in ELISA format, but displayed low affinity 
in an Octet system, which is similar to biacore and measure both on-rate and off-rate, 
indicating a high dependence on avidity for efficient binding. This is consistent with the 
low SHM rate displayed by GE147, with 1.4% divergence from germline on the 
nucleotide level. The other seven MAbs displayed a level of SHM more similar to the 
level observed in the total IgG+ MBC population in the same macaque, which is also 
similar to that observed following tetanus [140] or influenza vaccination [73]. In 
addition to gp120, to which all MAbs except GE147 displayed nM affinity, we also 
determined the affinity for the 2CC core. 2CC is an Env gp120 core stabilized in the 
CD4 bound conformation [378]. When measuring MAb binding it shows selective 
interaction with bNAbs in comparison to non-bNAbs and it was used successfully as a 
probe in flow cytometric single-cell sorts to isolate bNAbs [345]. Interestingly we 
detected binding, although at low affinity, to 2CC by MAb GE148 indicating the 
possibility that with the correct antigenic drive and additional SHM, this MAb lineage 
might be driven to elicit improved neutralizing activity. 
 
To evaluate the vaccine-induced MAbs functionally they were tested for neutralization 
of a panel of clade B viruses as well as one T cell lab adapted virus from clade A and 
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one from clade C. All MAbs except GE147 neutralized one or more viruses, with 
several MAbs neutralizing those of clade A and C indicating targeting of conserved 
regions within the CD4bs. These neutralization profiles were similar to non-bNAbs 
isolated from HIV-1 infected individuals. To further define the binding site of the 
individual MAbs, we performed a selected alanine (Ala) scan consisting of 27 gp120 
Env mutants each with an alanine substitution at a single residue [475]. Mutants were 
chosen that had previously been implicated in CD4 binding or interaction with CD4bs-
directed MAbs [229, 268, 358]. The Ala-scan revealed that the binding region of the 
vaccine-induced MAbs largely overlapped with that of the infection-induced non-
bNAbs. Additionally, when modeled in the context of the functional spike [235], the 
binding region of the vaccine-induced MAbs was shown to be more proximal to the 
trimer axis compared to that of the infection-induced, broadly neutralizing MAb, 
VRC01. We speculate that this is an angle of approach that potentially is occluded on 
primary virus Env spikes, explaining the limited neutralization breadth displayed by the 
vaccine-induced CD4bs-directed MAbs isolated in this thesis (Figure 23).  
 
 
Figure 23. gp120 core [229] modeled in a trimeric context in the cryo-EM derived native spike [235]. 
The spike is shown in side (left panel) and top (right panel) view. Circles indicate binding regions and 
highlighted amino acids indicate residues important for MAb binding. Red indicate vaccine-induced NHP 
MAbs and yellow the bNAb VRC01. Orange indicates overlapping residues. 
 
A further piece of information was obtained by testing neutralization to JRFL, a 
neutralization resistant virus, in which an N-linked glycosylation site was removed to 
disrupt the tight quaternary packaging of the Env spike (JRFLΔ301) [271]. While no 
neutralization was detected against the wildtype JRFL virus, effective neutralization 
was achieved against the JRFLΔ301 variant. Importantly, however, to get a complete 
understanding of the interactions between the MAbs and Env it will be necessary to 
crystallize the Abs in complex with antigen, experiments that are currently ongoing for 
GE148 and GE136. Although a panel of eight MAbs is only a small fraction of the Abs 
elicited toward the CD4bs following immunization, they provide a first step towards 
understanding why Env vaccine-elicited responses are not more broadly neutralizing. 
By defining the limitations with the current antigens, efforts can be made to attempt to 
restrict immune responses to broadly neutralizing surfaces on Env. 
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7.4.1 Ab breadth and potency elicited by trimeric Env versus monomeric Env 
Studies in small animal models have shown that soluble trimeric Env is superior to 
monomers in terms of eliciting Abs exhibiting neutralization breadth and potency [368, 
370, 476]. In paper I we therefore evaluated the trimeric Env-elicited Ab responses 
from three nonhuman primate studies [72, 112, 477] to gp120 monomeric responses 
elicited in twenty randomly selected human subjects from the VAX04 human clinical 
trial [367]. To do the comparison we evaluated the neutralizing capacity in plasma or 
serum against several tier 1 and 2 viruses from clade B and selected viruses from clade 
A and C using standardized methods [365] (Table III).  
 
Table III. Neutralization following immunization with monomeric or trimeric Env. 
   
VAX04b NHPc 
 
Virus Clade monomers trimers 
Tier 1 
MN B 100a 100 
HxB2 B 15 100 
SF162 B 5 100 
BaL0.1 B 0 37.5 
Tier 2 
YU2 B 0 75 
89.6 B 0 27 
6536 B 0 38 
ADA B 95 55 
Tier 1 DJ263 A 0 75 
Tier 1 MW965 C 95 100 
avalues indicate percent responders (ID50>10) vs non-responders (ID50<10)  
bn=20 randomly selected human donors from the VAX04 clinical trial. 
cn=16 macaques pooled from paper I, [477], and [112]. 
 
The plasma obtained from trimeric Env-immunized macaques expressed a broader 
neutralization profile with activities against all the viral isolates tested. The monomer-
induced human responses, on the other hand, showed a more narrow neutralizing 
profile, although when reactivity was detected it was generally potent. These responses 
indicate that the Env trimers used here elicit superior Abs breadth in the highly relevant 
translational macaque models in addition to small animals. However, it is also 
important to address the potential role of the different adjuvants for their capacity to 
influence the response. In this regard, Alum was used in the human study while AS01B 
or Abisco-100 together with CpG was used in the nonhuman primate studies, being a 
potential caveat to the comparison performed in paper I.  
 
7.5 ASSESSMENT OF PROTECTION FROM HETEROLOGOUS SHIV 
CHALLENGE 
Following immunization with Env a large proportion of the vaccine elicited antibody 
response is directed toward the variable regions [368, 373], which can protect against 
SHIV challenge with homologous virus [372, 478]. However, so far only partial 
protection against heterologous strains was observed [470, 479]. To evaluate the 
protective capacity of the Env-specific Abs elicited in paper I we first determined the 
neutralizing antibody titers in vitro to the CCR5 tropic SHIV-SF162P4. We observed a 
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moderate ID50 neutralization titer of ~200 against both the challenge virus and a cloned 
pseudovirus generated from the SHIV stock [479]. When performing repeated 
low/medium dose rectal SHIV-SF162P4 challenge a trend toward delayed infection and 
reduced viremia following infection was observed in Env-immunized animals 
compared to control animals. To investigate the basis for the limited protection, we 
determined the levels of Env-specific Abs at the virus portal of entry. We quantified the 
levels of Env-specific IgG and IgA in rectal and vaginal washes and analyzed these 
levels in relation to the circulating Abs in blood in each animal (Figure 24). 
 
Figure 24. Total IgG and Env-specific IgG antibody 
responses in plasma and in mucosal washes (n=21-24 
depending on successful sampling). Statistics was 
evaluated with ANOVA on log transformed values. 
 
 
 
 
 
 
Although there was a correlation between the plasma and mucosal compartments, the 
levels of Abs in the vaginal wash were 1000-fold lower and in the rectal wash 10 000-
fold lower than measured in circulation. Additionally, Env-specific IgA levels were 
below detection. This raises the possibility that the neutralizing antibody titers, 
although high in blood, were too low at the mucosal surfaces for efficient protection. 
These results highlight the importance of inducing Abs possessing specificities with 
enhanced neutralizing activity so that lower effective titers are needed. 
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8 CONCLUDING REMARKS 
With this thesis my aim was to provide an improved understanding of antigen-specific 
B cell responses following immunizations with protein-based vaccines. In particular, I 
used a recombinant trimeric HIV-1 Env glycoprotein as a model antigen as it is highly 
characterized both functionally and structurally in addition to being a clinically relevant 
vaccine candidate. In the studies included in this thesis, we immunized rhesus or 
cynomolgus macaques as a highly relevant model for human biology. By characterizing 
the Ab Ig loci from a rhesus macaque in paper III we further refined the model to 
facilitate analysis of B cell responses. We show that the human and rhesus Ig loci are 
highly homologous. Additionally following analysis of Ab V(D)J-segments from sorted 
cells in paper III and IV we confirmed that the gene usage was highly similar between 
different macaques as well as to that used in humans, further supporting the relevance 
of the macaque model for studies of human B cell biology. 
 
In papers I and II we developed several assays to enable the evaluation of cellular B 
cell responses and sought to determine the magnitude, durability, and quality of 
trimeric Env-specific B cell responses. We showed that recombinant trimeric Env elicit 
potent B cell responses with similar magnitude and kinetics as those of influenza and 
rabies vaccination. When comparing longitudinal samples from HIV-1 Env and 
influenza HA immunized macaques there was a similarly rapid contraction of antigen-
specific peripheral B cell responses following immunization, suggesting that soluble 
HIV-1 Env is not an unusually weak immunogen when administered in adjuvant, at 
least compared to influenza HA. Furthermore, in both papers I and II bone marrow 
resident plasma cells specific for HIV-1 Env were detectable, indicating that long-lived 
plasma cells were elicited through our immunizations. 
 
In addition to evaluating the magnitude and durability of B cell responses to trimeric 
Env, we also used several assays to gain insight in the quality of the elicited responses. 
In paper I we used a differential ELISpot [225] to show how the Env-specific memory 
B cell compartment developed from early gp41-specific responses to variable region 1-
3 specific responses during the immunization schedule. We further showed that despite 
no difference in magnitude of the antigen-specific B cell compartment there was a 
significant increase in neutralization titers to a panel of tier 1 and 2 pseudoviruses 
between the second and fifth immunization. This increase was likely due to Ab affinity 
maturation as indicated by an avidity assay. Furthermore, in paper II we show that the 
increase in Ab maturation was not necessarily dependent on repeated boosting as a 
similar increase was observed during a 29-week interval following only two 
immunizations, supporting the use of immunization schedules with long intervals 
between the second and third immunization [468]. 
 
We further compared the Env trimer-elicited neutralizing Ab responses from our 
immunized macaques with the responses elicited in a large clinical trial using 
monomeric Env and observed a improvement in the responses induced by the trimers. 
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These findings warrant further investigation in more controlled studies where the same 
adjuvant and HIV-1 Env strain is used in both groups. Such results would have direct 
implications for future clinical HIV-1 vaccine trials. 
 
Recently several bNAbs were isolated from chronically infected individuals. These Abs 
provide valuable information about vulnerable regions on the HIV-1 spike that can be 
targeted in vaccine design. We believe that in addition to isolating new bNAbs it is 
important to understand the responses elicited by current vaccine-candidates to inform 
immunogen-design efforts. In paper III we established a system for high-resolution 
evaluation of vaccine-induced B cell responses. We sorted Env-specific memory B 
cells recognizing a highly conserved Ab target, the primary receptor binding site 
(CD4bs), from the Env trimer-immunized animals described in paper I. We cloned and 
expressed a panel of Abs to determine qualitative differences to CD4bs-directed 
infection-induced bNAbs and non-bNAbs. Although all MAbs displayed similarly high 
affinity to recombinant trimeric Env they differed in neutralizing capacity. When 
mapping important residues for MAb binding to the CD4bs the vaccine-induced MAbs 
were shown to be dependent on residues located closer toward the center of the spike, 
likely being occluded in the tightly packed Env spike on primary virus strains, while a 
well-studied bNAb, VRC01, bound more distally on the outer domain of gp120, which 
likely is more accessible. These finding have implications for vaccine design as it may 
be possible to generate Env trimers that are more restricted in terms of which epitopes 
they expose. Finally, we adapted an RT-PCR-based protocol for the amplification and 
cloning of MAbs from sorted single cells to the rhesus macaque system in paper IV, to 
facilitate future efforts to characterize B cell responses at high resolution in rhesus 
macaques, an approach that has broad applications for studies of humoral immune 
responses. 
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9 FUTURE DIRECTIONS 
Nonhuman primates are invaluable as translational models for the evaluation of 
preclinical vaccine-candidates and for an improved understanding of human biology. 
Although recent improvement in the characterization of macaque B cell biology there is 
still a need for further studies to refine the model. Important aspects that need to be 
resolved are the flow cytometric definition of circulating plasma cells and long-lived 
plasma cells as well as improved insight in memory B cell subsets and distribution. 
These factors are highly important when evaluating B cell responses elicited by vaccine 
candidates. In addition to the definition of likely Ab germline repertoires as presented 
in paper III it will be important to characterize V(D)J-segment recombination and 
expression as functional Abs. 
 
Many of the CD4bs-directed bNAbs display specific characteristics, such as restricted 
gene family usage, commonly the IgHV1-2 segment (in humans). It will be important 
to determine if such restricted segments are also used in CD4bs-directed Abs following 
immunizations and if so, determine how they bind Env and if further affinity 
maturation of such Abs drives them in the right direction. As discussed in this thesis, 
the Env vaccine-induced B cell responses studied here appear to reach an affinity roof, 
corresponding to an average level of SHM, while bNAbs isolated from infected 
individuals display a considerably higher level of SHM. One important question for the 
future will be to identify strategies to promote SHM of vaccine-induced B cell 
responses. 
 
Although immunization with trimeric Env elicits Ab responses with improved 
neutralization breadth compared to monomeric Env, the breadth is still limited 
compared to broadly reactive responses in HIV-1 infected individuals. It will be 
important to continuously evaluate current and novel vaccine-candidates for iterative 
improvements in immunogen design to more selectively drive Ab responses to 
conserved and neutralization-sensitive regions on the Env spike. The methods 
described in paper III and IV will be valuable to meet this goal. An additional 
important future task is to crystallize vaccine-induced, CD4bs-directed MAbs with Env 
to obtain more definitive insights into the Ab-antigen interaction, knowledge that may 
lead to the design of improved vaccine approaches. 
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